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Abstract
A significant challenge facing the Air Force Medical Service (AFMS) Military
Treatment Facilities (MTFs) is the perishability costs associated with its pharmaceutical
stock. During a two year time period, the AFMS returned expired or nearly expired
pharmaceuticals valued at over $23,000,000. In response to the waste represented by
pharmaceutical perishability cost, this thesis analyzes the historical inventory
management decisions of 173 MTF/pharmaceutical combinations and proposes an
alternative inventory control policy to reduce perishability costs. Based on the critical
nature of pharmaceuticals and importance of generating high patient satisfaction, the
proposed alternative inventory control system was required to be cognizant of the cost
savings/service level trade-off. After applying a fundamental inventory management
equation to historical patient demands, the calculated inventory control policy is
evaluated against a recent nine month time period of patient demand in terms of potential
cost savings and fill rates. At the conclusion of the study, it is determined that the use of
the proposed inventory control policy would generate an effective perishability cost
savings of approximately $250,000 annually, as well as a one-time inventory reduction
cost savings that exceeds $1,700,000. In spite of this stock reduction, the studied
MTF/pharmaceutical combinations would maintain a strong fill rate that exceeds 99.82%.

iv

AFIT-ENS-MS-15-M-133

Dedicated to
My wife for her love, support, and the sacrifices she has made!
My parents for giving me every opportunity possible!

v

Acknowledgments
I would like to extend my sincere gratitude to my research committee, Dr.
William Cunningham and Lt Col Adam Reiman for their guidance and support
throughout the research process. I would also like to thank Mr. Christopher Canales of
the Air Force Medical Operations (AFMOA)/SGAL office for his assistance in
developing the research topic and providing the data necessary to complete the thesis.

Blake Smith

vi

Table of Contents
Page
Acknowledgments.............................................................................................................. vi
Table of Contents .............................................................................................................. vii
List of Figures ......................................................................................................................x
List of Tables ..................................................................................................................... xi
I. Introduction .....................................................................................................................1
Background .....................................................................................................................1
Problem Statement ..........................................................................................................3
Research Objectives/Questions .......................................................................................6
Methodology ...................................................................................................................6
Assumptions ....................................................................................................................8
Limitations ......................................................................................................................9
Implications ...................................................................................................................10
Thesis Organization ......................................................................................................11
II. Literature Review ..........................................................................................................12
Chapter Overview .........................................................................................................12
Inventory Management of Non-Perishable Items with Deterministic Demand ............14
Inventory Management of Non-Perishable Items with Stochastic Demand .................16
Inventory Management of Non-Specific Perishable Items ...........................................17
Inventory Management of Perishable Blood Donations ...............................................21
Inventory Management of Perishable Pharmaceuticals ................................................23
Summary .......................................................................................................................26
III. Methodology ...............................................................................................................28
Overview .......................................................................................................................28
Data Collection..............................................................................................................28
Estimation of Historical Inventory Positions ................................................................31
Calculation of an Alternative Order-Up-To Stock Level ..............................................33
Evaluation of the Alternative Stock Level ....................................................................35
Summary .......................................................................................................................39
IV. Results and Analysis ...................................................................................................41
Chapter Overview .........................................................................................................41
Travis AFB—Fosamax D 70 mg 5,600 IU ...................................................................41
vii

Wright Patterson AFB—Advair 250-50 Diskus ...........................................................44
Sheppard AFB—Tamiflu 75 mg ...................................................................................48
MTF/Pharmaceutical Combinations with Low Annual ITO Rates ..............................52
Summary .......................................................................................................................53
V. Conclusions and Recommendations ............................................................................57
Overview .......................................................................................................................57
Summary of the Research and Answers to the Research Questions .............................57
Recommendations for Action .......................................................................................59
Recommendation for Future Research ..........................................................................60
Appendix A ― Abilify 30 mg Results ..............................................................................62
Appendix B ― Acetasol HC Results .................................................................................63
Appendix C ― Advair 250-50 Results ..............................................................................64
Appendix D ― Agrylin 0.5 mg Results.............................................................................65
Appendix E ― Avonex 30 mg Results ..............................................................................66
Appendix F ― Celebrex 100 mg Results ..........................................................................67
Appendix G ― Celebrex 200 mg Results..........................................................................68
Appendix H ― Combivent 4 gm Results ..........................................................................69
Appendix I ― Epipen Results ...........................................................................................70
Appendix J ― Fosamax 70 mg / 2,800 IU Vitamin D Results..........................................71
Appendix K ― Fosamax 70 mg / 5,600 IU Vitamin D Results ........................................72
Appendix L ― Gleevec 100 mg Results ...........................................................................73
Appendix M ― Gleevec 400 mg Results ..........................................................................74
Appendix N ― Glucagon 1 mg Results ............................................................................75
Appendix O ― Januvia 100 mg Results ............................................................................76
Appendix P ― Lamictal 100 mg Results ..........................................................................77
Appendix Q ― Levitra 10 mg Results ..............................................................................78
Appendix R ― Mefloquine 250 mg Results......................................................................79
viii

Appendix S ― Nexium 40 mg Results ..............................................................................80
Appendix T ― Pancreaze 16,800 IU Results ....................................................................81
Appendix U ― Premarin 0.3 mg Results ..........................................................................82
Appendix V ― Premarin 0.625 mg Results ......................................................................83
Appendix W ― Premarin 1.25 mg Results .......................................................................84
Appendix X ― Prograf 5 mg Results ................................................................................85
Appendix Y ― Sandostatin 30 mg Results .......................................................................86
Appendix Z ― Spiriva 18 mcg Results .............................................................................87
Appendix AA ― Tamiflu 75 mg Results ..........................................................................88
Appendix AB ― Tobradex 5 ml Results ...........................................................................89
Appendix AC ― Votrient 30 mg Results ..........................................................................90
Appendix AD ― Vytorin 10 mg Results ...........................................................................91
Appendix AE ― Zemplar 4 mg Results ............................................................................92
Appendix AF ― Zytiga 250 mg Results ...........................................................................93
Appendix AG ― Quad Chart ............................................................................................94
References ..........................................................................................................................95

ix

List of Figures
Page
Figure 1: FY 2014 Unified Medical Budget Request ($billions) ...................................... 2
Figure 2: Projection of Healthcare Costs as a Percentage of the DoD Budget .................. 3
Figure 3: Fixed and Holding Costs Functions of the Order Quantity .............................. 15
Figure 4: Inventory Position Timeline for Premarin 0.625 mg at Altus AFB ................. 32
Figure 5: Example of Inventory Position Using the Alternative Stock Level ................. 36
Figure 6: Inventory Position Timeline for Fosamax D 70 mg at Travis AFB (Historical
Estimation) ....................................................................................................... 42
Figure 7: Inventory Position Timeline for Fosamax D 70 mg at Travis AFB Using the
Alternative Order-Up-To Stock Level ............................................................. 43
Figure 8: Inventory Position Timeline for Advair 250-50 at Wright Patterson AFB
(Historical Estimation) ..................................................................................... 45
Figure 9: Inventory Position Timeline for Advair 250-50 at Wright Patterson AFB Using
the Alternative Order-Up-To Stock Level........................................................ 47
Figure 10: Daily Inventory Position Timeline for Tamiflu 75 mg at Sheppard AFB
(Historical Estimation) .................................................................................... 49
Figure 11: Inventory Position Timeline for Tamiflu 70 mg at Sheppard AFB Using the
Alternative Order-Up-To Stock Level ............................................................ 51

x

List of Tables
Page
Table 1: Underlying Assumptions of the EOQ Model .................................................... 14
Table 2: Pharmaceuticals Chosen for Inventory Analysis ............................................... 29
Table 3: Order-Up-To Level Calculation for Celebrex 200 mg at Goodfellow AFB ..... 35
Table 4: Order-Up-To Level Calculation for Fosamax D 70 mg at Travis AFB ............ 43
Table 5: Evaluation Results of Fosamax D 70 mg 5,600 IU at Travis AFB ................... 44
Table 6: Order-Up-To Level Calculation for Advair 250-50 at Wright Patterson AFB . 46
Table 7: Evaluation Results of Advair 250-50 at Wright Patterson AFB........................ 48
Table 8: Order-Up-To Level Calculation for Tamiflu 75 mg at Sheppard AFB ............. 50
Table 9: Evaluation Results of r Tamiflu 75 mg at Sheppard AFB ................................. 52
Table 10: MTF/Pharmaceutical Combinations with Annual ITO Rates Below 2 ........... 52
Table 11: Summary of Results by Pharmaceutical .......................................................... 54
Table 12: Sensitivity Table for Effective Perishability Cost Savings.............................. 55

xi

I. Introduction
Background
As the United States’ (U.S.) debt position soars past eighteen trillion dollars
(www.usdebtclock.org), pressures continue to mount in favor of reduced federal
spending. Based on this sentiment, the Future Year Defense Program (FYDP) budget
has become a target of considerable scrutiny. This is primarily based on the fact that the
Department of Defense (DoD) consumes the largest portion of the federal government’s
discretionary spending authority. Receiving the most scrutiny within the DoD budget is
the unsustainable growth of personnel costs. The Secretary of Defense (SECDEF)
weighed in on the issue during a speech that he delivered to the Center for Strategic and
International Studies on November 5, 2013.
Without serious attempts to achieve significant savings in this area [military
personnel costs] — which consumes roughly half of the DoD budget and is
increasing every year — we risk becoming an unbalanced force ... one that is
well-compensated, but poorly trained and equipped, with limited readiness and
capability.
Chuck Hagel,
Secretary of Defense (2013)
Military personnel costs accounted for approximately 130 billion dollars of the
overall 512 billion dollar fiscal year (FY) 2014 DoD budget (Office of Management and
Budget, 2013). While military personnel costs are comprised of significant budgetary
line items such as base pay, allowances, and retired pay accrual, it is the rapid escalation
of defense related healthcare costs that has led many to conclude that current policies are
unsustainable (Rugy, 2014). Figure 1 displays the breakdown of the 49.4 billion dollar
FY 2014 budget associated with military healthcare costs, accounting for approximately
1

9.39 percent of the overall defense budget. This current portion of the overall defense
budget is up from approximately 6 percent in FY 2000.

Figure 1: FY 2014 Unified Medical Budget Request ($billions)

The most alarming aspect of the defense healthcare cost is that it is projected to
expand at a rate much higher than other defense related costs. The Congressional
Budget Office (CBO) projects that the defense healthcare cost will skyrocket to 95
billion dollars by FY 2030, accounting for over 14% of the nation’s projected defense
requirement of the same year (Jansen, 2014:17). Figure 2 displays a graphical
representation of the CBOs projection of defense related healthcare costs consuming
larger portions of the overall defense budget in future years.
An additional challenge facing the DoD is the Budget Control Act of 2011, which
constrains defense related spending through the year 2021. In this fiscally constrained
environment, the continuation of rapidly escalating healthcare costs could force the DoD
to make difficult tradeoff decisions and reduce spending in areas such as force structure,
military readiness, and weapons modernization (Congressional Budget Office, 2014).
These types of actions have become reality with the President’s proposed 2015 defense
budget calling for a reduction in force structure across all military services along with
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the retirement and cancellation of other weapon systems (Simeone, 2014). Current
strategies to control the DoD’s rising healthcare costs have largely focused on proposals
that shift financial burdens to military personnel by raising enrollment fees, deductibles,
or copayments (Rugy, 2014). While these measures may prove to be necessary in
sustaining future military capabilities, the DoD must first perform a fundamental review
of its healthcare delivery methods in search of opportunities that increase efficiencies
while maintaining a high level of service for its beneficiaries.

Figure 2: Future Year Projection of Healthcare Costs as a Percentage of the DoD Budget

Problem Statement
One healthcare delivery method that is fitting of such a fundamental review is the
distribution of pharmaceuticals. Pharmaceuticals are a primary contributor to the
escalating healthcare costs shouldered by the DoD. The DoD’s pharmaceutical costs
have expanded from approximately three billion dollars in 2002 to approximately 6.8
billion dollars in 2011, outpacing the overall pharmaceutical sales rate in the U.S. by
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nearly double. To put this into perspective, the DoD spent more resources on
pharmaceuticals than it did on Black Hawk helicopters, Abrams tanks, Hercules C-130
cargo planes and Patriot missiles—combined (Schwartz & McDonald, 2013).
The DoD provides pharmaceutical benefits to its eligible beneficiaries by means
of three distinct delivery methods. These three methods include local retail pharmacies,
mail-order service, and DoD Medical Treatment Facility (MTF) distribution. Studies
have shown that pharmaceuticals delivered through the retail pharmacy method cost the
DoD more than when the same pharmaceuticals are delivered through the mail-order and
MTF distribution methods (Rand Corporation, 2005). The primary reason that the MTF
distribution method is most cost effective on a per prescription basis is that it utilizes a
prime vendor for all pharmaceutical supplies. On January 25, 2005, the Defense
Logistics Agency (DLA) awarded the Pharmaceutical Prime Vendor (PPV) Generation
III contract to AmerisourceBergen Drug Corporation for TRICARE regions North and
South and to Cardinal Health Inc. for TRICARE West (Defense Logistics Agency,
2014).
The PPV Generation III contract provides multiple benefits to the MTFs of all
military branches. One of the key benefits of the contract is the ten year pricing
agreement with declining distribution fees as the contract ages. It is the combined
purchasing power of all DoD MTFs across the Contiguous United States (CONUS) and
the pricing agreement included in the PPV Generation III contract that enables the MTF
pharmacies to dispense prescriptions to TRICARE beneficiaries in a cheaper manner
than their retail counterparts. Additionally, the PPV Generation III contract provides
contractual fill rates that range between 95 and 98 percent and include a one business
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day delivery lead time. Although the PPVs are contractually responsible for filling 95 to
98 percent of MTF’s daily pharmaceutical requirements, their historical performance has
far exceeded this obligation. A secondary “back-up” contract is also in place to be
utilized in the event that the PPV cannot fill an MTF requirement (Defense Logistics
Agency, 2014). The high fill rates and shortened delivery lead times afforded by the
PPV Generation III contract should be leveraged by the MTFs to reduce their respective
pharmaceutical inventories.
Despite this fact, there is evidence to suggest that Air Force Medical Service
(AFMS) MTFs have not seized this opportunity to reduce pharmaceutical inventories.
Per the Air Force Medical Operations Agency (AFMOA)/SGAL office, the aggregated
value of pharmaceutical inventory positions across all Air Force MTFs is in excess of
134 million dollars. The same AFMOA/SGAL office estimates that the aggregated
inventory position across all AFMS MTFs should be closer to a value of 32 million
dollars. Perhaps the most alarming evidence suggesting that the AFMS currently holds
too much pharmaceutical inventory is based on the fact that it returned a significant
amount of pharmaceuticals that were either past its expiration date of clinical
effectiveness or nearing the expiration date. Over the two year time period of September
2012 through September 2014, these returns were valued at over 23 million dollars.
While the PPV Generation III contract provides a mechanism for MTFs to recoup
approximately 40 percent of the sale price for the return of pharmaceuticals with a
remaining lifespan of clinical effectiveness, the pharmaceuticals returned through the
reverse distribution vendor represent waste within the process.
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Research Objectives/Questions
Given the problem, the purpose of this study is to identify an ordering policy that
would reduce the AFMS’ pharmaceutical inventory position, while maintaining a high
level of patient prescription fill rates. The overarching objective is to demonstrate a
potential for cost savings that can be achieved through a sound ordering control policy
and the execution of inventory management procedures applied to the AFMS’
pharmaceutical supplies. In the pursuit of this objective, three research questions will be
addressed:
1. What cost savings can the AFMS realize in terms of reducing the amount of
expired or near expired pharmaceutical returns, given the application of an
inventory control system that utilizes adjusted order-up-to stock level quantities?
2. What cost savings can the AFMS realize in terms of reducing on-hand
pharmaceutical stock, given the application of an inventory control system that
utilizes adjusted order-up-to stock level quantities?
3. What impact will the proposed inventory control system have on pharmaceutical
fill rates?
Methodology
This study uses a multiple phased methodology approach to address its three
research questions. As with most research efforts, the initial phase of this study
consisted of collecting pertinent data sets. The first set of data collected was that of the
AFMS pharmaceutical returns over a two year time period. Along with providing the
motivation for the study altogether, the pharmaceutical returns data was used to focus
the study on the inventories of 32 distinct pharmaceuticals across all CONUS MTFs.
Because not all CONUS MTFs recorded returns of the 32pharmaceuticals, the study
performed inventory analysis that culminated over 173 MTF/pharmaceutical
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combinations. Additionally, patient pharmaceutical demand records, PPV sourcing
records, and the Defense Medical Logistics Standard Support (DMLSS) Customer Area
Inventory Management (CAIM) suggested levels were collected for use in subsequent
phases of the methodology.
The next phase of the methodology consists of constructing an estimate of the
historical inventory positions for the respective MTF/pharmaceutical combinations.
This estimation is a necessary step based on the actual inventory positions not being
available for use in this study. Therefore, an estimated daily timeline of historical
inventory positions for the respective MTF/pharmaceutical combinations were
constructed by using the daily patient demand records, PPV sourcing records, and the
number of units returned to the reverse logistics vendor.
The primary challenge with the reconstruction of the daily inventory positions
was the absence of a starting inventory position on the first day of analysis (1/1/2012).
In lieu of the actual starting inventory position, the study used the DMLSS CAIM
suggested level for its starting inventory position. The one exception to using the CAIM
suggested level takes place if that level allows the inventory position to fall below zero,
signifying a stockout. Because the patient demand data is actually representative of the
prescriptions filled by the MTF pharmacies, stockouts were not permitted in the
recreation of the historical inventory positions. In these cases, the starting inventory
position was raised to the minimum level that ensured zero stockouts occurred in the
historical reconstruction of the inventory positions.
The third phase of the methodology consists of calculating an alternative orderup-to stock level for each of the respective MTF/pharmaceutical combinations. A basic
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inventory management equation is applied to the 1/1/2012 through 12/31/2013 patient
demand data to determine an appropriate order-up-to stock level. Upon the completion
of these calculations, the alternative order-up-to stock levels are evaluated with respect
to the patient demand data under the time period of 1/1/2014 through 9/19/2014. The
alternative order-up-to stock levels are evaluated in terms of cost savings and
pharmaceutical fill rates, thereby providing answers to the study’s three research
questions.

Assumptions
The primary assumption of the study is that the collected data is accurate and
representative of the actual pharmaceutical inventory transactions that took place over
the three year span. This is a reasonable claim, based on the fact that the data sets were
collected directly from their official record keeping systems (i.e., DMLSS and the
Military Health System Management Analysis and Reporting Tool). The study also
makes three additional assumptions in an effort to reduce complexity within the
inventory analysis.
The first of these assumptions is that the research effort will use a fixed value of
six months to represent the individual pharmaceutical’s lifespan of clinical effectiveness
in the inventory analysis. The six month value was chosen based on the fact that it
represents the shortest acceptable lifespan of a newly supplied pharmaceutical as
prescribed in the PPV Generation III contract. This life expectancy assumption
undertakes a conservative approach, based on it representing the worst case scenario.
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The second assumption found within the study is that it treats the delivery lead
time of all pharmaceuticals as a deterministic value of one business day. This
assumption was based on the PPV Generation III contract parameters and the vendor’s
historical demonstration of meeting this requirement on nearly all occasions. The final
assumption of the study is that the inventory model will assume a First-In First-Out
(FIFO) distribution policy. This is common practice of all pharmacies, where the newest
pharmaceuticals are placed behind older pharmaceuticals in the pharmacy shelving.

Limitations
Based on time and data constraints, this study possesses three limitations that
must be considered. The first limitation is that the study will focus on only the
pharmaceutical inventory management practices of Air Force (AF) MTFs within the
CONUS. While many of the principles introduced in this study are applicable to the
MTFs of other military services and MTFs Outside [the] Contiguous United States
(OCONUS), the results found in this study cannot be generalized to those MTFs.
The second limitation found within the study is that analysis could not feasibly be
performed on the 15,098 distinct pharmaceuticals that were returned by AFMS MTFs
over the two year period. While the study performs analysis on only 32 of these
pharmaceuticals, an attempt to reduce this limitation was made by focusing on the
pharmaceuticals that exhibited the greatest portion of returns as measured by dollar
value.
The third limitation found within the study is that patient demand, PPV sourcing,
and returns data is aggregated across all pharmacies operating under the authority of a
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MTF. This is a potential limitation to the study based on the common practice of most
MTFs operating a main pharmacy within the primary clinic facility, while also operating
a “refill” pharmacy that is typically located in an area near the Base Exchange or
Commissary. While this limitation has the potential to affect the savings and fill rate
calculations, the magnitude of the loss in precision should be minimal.

Implications
The Department of Defense is facing a legitimate challenge in the form of rising
healthcare costs. As referenced before in the background section of this chapter, the
CBO projects that the defense healthcare cost will skyrocket to $95 billion by the year
2030, accounting for over 14% of the nation’s projected defense requirement in the same
year (Jansen, 2014). As healthcare costs are projected to surge within the Department of
Defense budget, civilian and military leaders will be forced to choose between a
potential reduction in healthcare benefits for beneficiaries or a reduction in war fighting
capabilities (personnel and weapon systems). The only solution to avoiding this
unenviable position is to reduce or at the very least slow the growth of military
healthcare costs.
While this study in pharmaceutical supply operations does not intend to present
the grand illusion of solving the challenge of rising healthcare costs in one fell swoop, it
does provide a starting point from which to begin. Along with the modest cost reduction
that the proposed research study intends to accomplish, it will also provide momentum
for additional research within the Air Force Medical Service to be initiated.
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Thesis Organization
This thesis is comprised of five chapters. Chapter 2 provides a summary of extant
literature that is relevant to the research questions posed in Chapter 1. The summary of
relevant literature is further categorized into the inventory management of nonperishable items with deterministic demand, non-perishable items with stochastic
demand, non-specific perishable items, perishable blood donations, and concludes with
the inventory management of perishable pharmaceuticals. Chapter 3 summarizes the
methodology used in this research effort. The primary phases of the methodology
include data collection, estimation of historical inventory positions, the calculation of an
alternative order-up-to stock level, and concludes with an evaluation of the alternative
order-up-to stock level. Chapter 4 presents the results and analysis of the performed
methodology. Chapter 5 provides a summary of the study by answering the research
questions and concludes the thesis with recommendations for action and future research.
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II. Literature Review
Chapter Overview
The inventory management discipline has been studied extensively by operations
research analysts and practitioners alike. The primary objective of the inventory
management discipline is for an organization to determine inventory policies for
individual products that result in the maximum net benefit. In other words, the
organization seeks the optimal levels of inventory that allows for the fulfillment of
customer demand while also limiting the costs associated with holding excess inventory.
The study of inventory management can be separated into two categories; products
exhibiting indefinite or long term life expectancies and products possessing fixed finite
life expectancies. The products possessing fixed finite life expectancies are commonly
referred to in the extant literature as perishable items. Examples of perishable items
include amongst others: grocery items, seasonal fashion items, blood donations, and
pharmaceuticals.
Despite the perishability factor of pharmaceuticals, this literature review will
begin by briefly introducing the contributions of early studies focusing on the derivation
of optimal inventory management policies for non-perishable products. The decision to
include non-perishable inventory management studies stems from the fact that these
studies set the foundation for the much more complex studies of perishable inventory.
The literature review of non-perishable inventory management studies will be separated
into those with a deterministic product demand rate and those with a stochastic product
demand rate.
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Upon the completion of the non-perishable inventory management section, the
remaining focus of this chapter will be to review the extant literature that is associated
with the inventory management of perishable products. The remaining review of extant
literature on the inventory management of perishable products will be separated into
three sections. The first section will introduce studies that pertain to the general
discipline of perishable inventory management. This section will include the
fundamental studies that provided the foundation for expanded studies that specifically
address the inventory management policies of perishable items related to the effective
and efficient delivery of healthcare.
The second section of the remaining literature review will introduce the extant
research that focuses on the management of blood donation inventories. Soon after the
fundamental ground work for the discipline of perishable inventory management was
set, the inventory operations of blood banks became a popular topic amongst operations
research analyst. One explanation for the popularity of the blood bank research stems
from the high stakes that are associated with whole blood availability for transfusions
and other medical procedures. The literature review will conclude with an introduction
to the extant research conducted on the inventory management practices of
pharmaceuticals. While studies on pharmaceuticals have not yet reached the prevalence
attained by blood bank research, it is growing in response to the significance that
pharmaceuticals play in the overall cost of healthcare delivery.
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Inventory Management of Non-Perishable Items with Deterministic Demand
Perhaps the most fundamental paradigm in the discipline of inventory
management ensued with Ford Whitman Harris’ derivation of the Economic Order
Quantity (EOQ) calculation. In his article, titled How Many Parts to Make At Once,
Ford Whitman Harris describes an economic quantity calculation for determining the
optimal production lot size for the manufacturing industry (Harris, 1913). While there is
some debate over who was the first to expand Harris’ original work on the EOQ, it was
quickly modified and applied to the inventory control problem of determining the
optimal order quantity for an individual product (Erlenkotter, 1990). Harris’ basic EOQ
model requires underlying assumptions to be made upon the circumstances of the
inventory item being analyzed (Silver, Pyke, & Peterson, 1998). Table 1 displays the
eight underlying assumptions of the EOQ model below:
Table 1: Underlying Assumptions of the EOQ Model

●
●
●
●
●
●
●
●

EOQ Assumptions
The product demand rate is constant and deterministic
There are no minimum or maximum restrictions on the size of an order
The unit variable cost is fixed
The cost factors do not change with time
No shortages/backorders are permitted
The delivery lead time for a product is fixed
The entire order quantity is delivered at the same time
Substitutions of products are not permitted

Given these assumptions, the basic EOQ model determines the order quantity that
minimizes the total cost by assessing the tradeoff between a fixed ordering cost and a
holding cost represented as a percentage of the unit variable cost in stock (Muckstadt &
Sapra, 2010). Figure 3 displays the fixed and holding costs as functions of the optimal
order quantity (Q*).
14

Figure 3: Fixed and Holding Costs Functions of the Order Quantity (Muckstadt &
Sapra, 2010)
The basic EOQ formula is then given as:

Where

2𝐾𝜆

EOQ = � 𝐼𝐶

(1)

K = Fixed Order Cost
λ = Annual Demand Rate of the Product
I = Holding Cost (% of unit variable cost)
C = Unit Variable Cost
With the optimal order quantity calculated with respect to the underlying
assumptions, the final piece of the inventory control policy needed is the determination
of the reorder point. Since the on hand inventory position of an item is assumed to be
zero upon replenishment, the inventory level upon which a replenishment order is
requested is equal to the demand of the product (λ) during the lead time (τ) of the
replenishment. Therefore, the reorder point (r) for the basic EOQ model is equal to λτ.
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Inventory Management of Non-Perishable Items with Stochastic Demand
While the EOQ is regarded as the fundamental paradigm for the inventory
management discipline, it is often criticized for its restrictive underlying assumptions.
The main assumption of the basic EOQ model that does not correspond with reality is
the assumption of the product demand exhibiting a constant and deterministic rate. In
reality, the product demand rate is stochastic. With a stochastic product demand rate,
the organization must forecast the product demand rate while also accounting for the
variability of the forecast by including a safety stock level to buffer against the threat of
a product stockout.
The two most common approaches to determining a safety stock level are through
a basis of minimizing cost as well as a basis of meeting a predetermined customer
service level (Silver, Pyke, & Peterson, 1998). The approach based on minimizing cost
explicitly or implicitly assigns a cost to a stockout occurrence and then attempts to
minimize the total cost by assessing the tradeoff between the stockout cost and the
holding cost of excess inventory. The approach based on meeting a predetermined
customer service level uses statistical analysis of the product demand lead time to
determine the appropriate safety stock level that is necessary to attain or exceed the
service level constraint.
Facing the reality of a stochastic product demand rate, the majority of nonperishable inventory management literature focuses on the derivation of optimal or nearoptimal stock levels with regards to three common inventory control policies (Silver,
Pyke, & Peterson, 1998). The first inventory control policy is referred to as the OrderPoint, Order-Quantity (s, Q) policy. This inventory control policy features a fixed

16

quantity (Q) being ordered whenever the inventory position of an individual product
drops below the reorder point (s). The second policy is referred to as the Order-Point,
Order-Up-To level (s, S) policy. Similar to the previous (s, Q) inventory control policy,
the (s, S) policy places a replenishment order when the individual products inventory
position drops below the reorder point (s). The difference between the two policies is
that the (s, S) policy places a replenishment order with a variable quantity that equals the
difference between the order-up-to level and the net inventory position.
The third and final inventory control policy that is commonly found in the extant
literature is referred to as the Periodic-Review, Order-Up-To-Level (R, S) policy. The
(R, S) policy has a predetermined time interval for reviewing the inventory position of
an individual product (i.e., once a day, once a week, etc.). During this periodic review
of the inventory position, a replenishment order is made in the amount equal to the
difference between the Order-Up-To-Level (S) and the individual product’s net
inventory position. This is essentially the inventory control policy used by AFMS
pharmacies.

Inventory Management of Non-Specific Perishable Items
One of the fundamental contributors to the research of perishable inventory
management practices is Dr. Steven Nahmias of Santa Clara University. In one of his
earliest works, entitled Optimal Ordering Policies for Perishable Inventory―II,
Nahmias (1975) develops a single period model for a single perishable product where an
assumption is made that replenishment orders are placed at the beginning of each period
and are received instantaneously (no positive lead time). In pursuit of minimizing costs

17

associated with various ordering policies, the overall cost of the inventory policy is
charged linearly for ordering, holding, stockout, and expiration costs. When Nahmias
attempts to derive the optimal ordering policies of a single perishable product in a multiperiod time horizon, he finds that with the exception of products with very short life
expectancies, the computations are not realizable.
Nahmias (1982) followed this study by completing a summary and review of the
extant research in the field of perishable inventory theory up until the 1982 date of
publishing. Nahmias begins by distinguishing the attribute of inventory perishability as
either fixed lifetime or random lifetime. Since the expiration date associated with all
pharmaceuticals represents a definitive date of clinical effectiveness, the author’s review
of fixed life perishability is most pertinent to the AFMS pharmaceutical research effort.
Nahmias’ study further categorizes fixed life perishability into deterministic and
stochastic product demands. Nahmias begins by reviewing research applying a periodic
review with known demand, as found in a dissertation effort by A. F. Veinott (1960).
Unfortunately, these assumptions are not practical for application based on the
occurrence of demand changing over time in reality.
Nahmias proceeds to introduce the research that had been conducted on
perishable products with stochastic demand. Echoing a conclusion from his previous
work, he states that when demand is stochastic and the life expectancy of the product
exceeds one period, the computation of optimal ordering policies is extremely difficult.
Nahmias acknowledges the first researcher to tackle a two period life expectancy
problem was G. J. Van Zyl. Van Zyl (1964) modeled the two period life expectancy
product with respect to the proportional costs of ordering and stockouts. Similarly,

18

Nahmias and Pierskalla (1973) modeled the two period life expectancy product with
respect to the costs of stockouts and product expiration.
Expansion of the research into inventory optimization models for perishable
products exceeding a fixed life expectancy that was greater than two periods was
developed simultaneously and independently by Fries (1975) and Nahmias (1975).
Their research showed that an increase of initial stock of inventory of any age by one
unit will decrease the optimal order quantity by less than a single unit. Despite this
finding, the researchers found that the computational time of using either model for
product life expectancies greater than or equal to three periods is difficult and
impractical for a real problem.
Nahmias later teamed up with Charles P. Schmidt (1985) to study the modeling of
(S-1, S) policies for a single perishable item with a fixed and known life expectancy. A
(S-1, S) inventory control policy suggests that an order is placed for exactly one unit at
each occurrence of a product demand and at each occurrence of a product expiration in
the case of perishable items. The significance of this study is that it was the first of its
kind to incorporate a positive lead time for product replenishment. Using this model,
Schmidt & Nahmias display a sensitivity analysis that demonstrates the impacts of
various levels of product life expectancy and replenishment lead times on the optimal
value of S, as well as the expected annual cost for the indicated parameters. The early
works by Nahmias and other pioneers in the study of perishable inventory management
laid the groundwork for others to expand upon their work and focus on specific
assumptions and control models of perishable inventory.
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B. C. Giri & K. S. Chaudhuri (1998) pursue an EOQ-type inventory model
approach with a demand rate that is dependent on the on-hand inventory stock level of
the specified perishable product. This is based on the Levin et al. (1972) research that
suggested "at times, the presence of inventory has a motivational effect on the people
around it. It is a common belief that large piles of goods displayed in a supermarket will
lead the customer to buy more". The primary significance of the Giri & Chaudhuri
article is that they treat the holding cost parameter of the EOQ model as a nonlinear
function of the length of time for which the item is held in stock.
Liming Liu & Zhaotong Lian (1999) expand the body of knowledge by analyzing
a (s, S) continuous review perishable inventory model with a general renewal demand
process and instantaneous replenishment of ordered stock. Inspired by a lack of extant
literature addressing the optimization of a continuous review perishable inventory
model, the Liu & Lian use a Markov renewal approach to obtain closed-form solutions
for the steady state probability distribution of the inventory level. Additionally, the Liu
& Lian use a closed-form expected cost function to study the impact of various
parameters. The Liu & Lian study concludes that because the distribution of the
objective function is not affected by the coefficient of variation of the demand process, it
is reasonable to believe that the (s, S) policy is the optimal model for general renewal
demand processes.
Hideki Katagiri & Hiroaki Ishii (2002) address the ambiguity of accurately
estimating the cost of stockouts and expiration cost as constant values when considering
perishable inventory problems. The researchers derived a single-period inventory model
of perishable products using "fuzzy numbers" for the stockout and expiration costs. The
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authors introduce the fuzzy max order, derived by N. Furukawa (1994), to define nondominated ordering quantities for maximization of expected profits as solutions to the
perishable inventory problem.
Fredrik Olsson & Patrik Tydesjö (2010) expand upon the Schmidt and Nahmias
(1985) research to consider a single perishable product with a Poisson demand, fixed life
expectancy, and fixed replenishment lead time. Fredrik Olsson & Patrik Tydesjö apply a
(S-1, S) policy for stock replenishments. The authors consider three different cases
where service level requirements are represented by stockout costs per unit, a service
level constraint, and stockout costs per unit and time. The authors conclude the study
with a sensitivity analysis of the three cases using various parameter inputs.

Inventory Management of Perishable Blood Donations
One of the earliest applications of the perishable inventory management research
topic was on the management of whole blood units within local and regional blood
banks. Donated blood is a valuable commodity for medical treatment of conditions
requiring transfusions. The American Red Cross estimates that someone in the U.S.
requires blood every 2 seconds of the day (www.redcrossblood.org). The complexity
surrounding the management of whole blood units is the requirement of needing a robust
supply of the blood units on hand to respond to medical emergencies along with the
constraint of its perishability. Blood bank managers are faced with the daunting task of
ensuring the availability of all blood type units for use in life saving procedures, while
also attempting to limit the spoilage rate of such a valuable and limited resource. The
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review below will introduce a sample of research that was conducted in search of
improving the effectiveness and efficiency of blood inventory management.
Gregory Prastacos (1984) provides a comprehensive overview of the theory and
practice of blood inventory management. One of the primary research efforts reviewed
by Prastacos was conducted by J.B. Jennings. Jennings (1968) used a simulation to
evaluate blood bank performance and derive trade-off curves displaying the events of
expiration vs. stockouts as functions of the inventory levels. Prastacos suggests that the
trade-off decisions between stockouts and expiration rates typically differ amongst the
various blood types. Because the demand rate of rarer blood types must be stocked
proportionally higher than common blood types to achieve the same stockout rates, they
result in higher expiration rates.
A study of a large hospital in Philadelphia agreed with this notion as their
expiration rates of rare blood types were dramatically higher than common blood types
(Prastacos, 1984). The author suggests that this finding justifies the common practice of
some hospitals not to stock the rare types. This generalization can be applied to the
process of pharmaceutical formulary management. In order to limit the degree of
pharmaceutical expiration rates, the medical staffs of healthcare facilities should be
selective in their decisions to add new pharmaceuticals to the formulary. Additionally,
medical staffs should conduct periodic reviews of their medical facilities’ formulary to
determine if any currently stocked pharmaceuticals should be removed from the
formulary with respect to a declining future patient demand.
Dan Chazan & Shmuel Gal (1977) approach the blood inventory management
quandary by using a Markovian model to compute the upper and lower bounds of the
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average number of whole blood units exceeding its useful life expectancy versus a total
number of inventory units in stock. The Markovian model was chosen to answer the
research question of determining how much inventory could be held, and therefore
reduce the risk of stockouts, without significantly increasing the number of blood units
being discarded based on it exceeding its useful life expectancy.
David Perry (1997) provides a unique approach by using a double band control
policy to model the blood bank perishability problem. With the number of items
arriving during the age of the oldest item representing the model's stock level, the stock
level of whole blood units is assumed to fluctuate as an alternating two-sided regulated
Brownian motion between the barriers of expiration (represented by a value of 0) and
stockout (represented by a value of 1). The model also assumes that the decision maker
of the blood bank is able exercise control on the rates of arrival and demand. Therefore,
the model includes two switchover levels that are positioned between the values of 0 and
1 (0 ≤ a < b ≤ 1). When the stock levels reach the determined levels of a or b, the model
assumes that the manager of the blood bank implements the appropriate measures to
alter the arrival or demand of the blood units.

Inventory Management of Perishable Pharmaceuticals
While there is currently not a significant amount of extant literature dedicated to
the management of pharmaceutical inventories, it is a research topic that has recently
been pondered by a growing number of operations research analysts. Although the
majority of pharmaceuticals possess a longer fixed life expectancy than that of whole
blood units, the inventory management of both products share the difficult tradeoff
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decision between the requirements for maintaining a robust on hand inventory to meet
patient demand with the conflicting constraint of limiting the waste associated with
product expiration. The trade-off decision between costs and the level of required
service is more complex and difficult to manage in the health care setting than it is in the
manufacturing industry.
While the impact of stockouts in the manufacturing industry can be significant
through the threat of lost sales, a stockout of critical pharmaceuticals and whole blood
units can be harmful to the wellbeing of a patient in need. Although stockouts of blood
units typically pose a more immediate threat to the health of patients in need, the impact
of understocking pharmaceuticals can lead to increased dissatisfaction of physicians and
a declining operational performance of the overall health care facility (Vries, 2011). J.
Vries states that a proper balance between service metrics and costs is without a doubt
the main logistical challenge that hospitals are faced with.
Another complexity that the inventory management of blood units and
pharmaceuticals share stems from the fact that they both possess product demand rates
that exhibit non-stationary behavior. There are three factors that cause patient demand of
pharmaceuticals to be non-stationary. These factors include the change in patient
condition dynamics, seasonalities, and the shifting of dosing requirements triggered by
changes in patient characteristics such as age, weight, and blood pressure. Additionally,
pharmaceutical demand is a function of the patient population mix from which the health
care facility services. Despite the non-stationary behavior of pharmaceutical demand
rates, early research on the topic of pharmaceutical inventory management treated the
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demand rates as stationary and therefore possesses a lessened degree of validity (VitaParrish & Ivy, 2013).
Vita-Parrish & Ivy (2013) provide a detailed summary of three unique studies that
treated the pharmaceutical demand rate as stationary. Little & Coughlan (2008)
developed a stock level optimization model that accounted for storage space constraints,
item criticality, and delivery frequency. One of the primary findings by Little &
Coughlan was that the same patient service levels can be achieved by receiving
replenishment deliveries on a daily basis with low space usage compared to the receipt
of replenishment deliveries every three to five days with a high space usage. Claudia
Rosales (2011) compared out-of-cycle and continuous review (s, S) replenishment
policies of pharmaceuticals. Rosales’ study concluded that a hybrid policy composed of
the primary (s, S) policy and an out-of-cycle replenishment of a fixed order if stock
positions reached a specified threshold was optimal. Derrek Descioli (2005) studied the
performance of various inventory control policies within automated point-of-use systems
under the condition of intermittent demand rates. The intermittent demand rates used in
Descioli’s model was a progressive step towards a dynamic demand model that
incorporates non-stationary demand.
Anita Vila-Parrish, Julie Ivy, & Russell King (2008) were the first credited
researchers to approach the inventory management of pharmaceuticals topic with a nonstationary demand rate. Vila-Parrish, Ivy, & King used a simulation based approach to
model the inventory and ordering policies of an inpatient hospital pharmacy, where the
model defines the patient demand of the individual pharmaceuticals as a function of the
patient's condition. The study includes simulations of stationary and non-stationary
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demand rates for comparison. The first policy, termed the "Fixed Policy", forecasts
patient demand of pharmaceuticals based solely on historical demand. The second
policy, termed "Adaptive Policy" uses the number and type of patient admitted to the
inpatient facility. The results of the simulation show that the "Adaptive Policy" resulted
in a lower total cost when compared to the "Fixed Policy" within the defined experiment
set.
Vila-Parrish et al. (2012) expanded their previous study by modeling two stages
of inventory with a production stage. The two separate stages of inventory come in the
forms of raw materials and finished goods (e.g. intravenous medications), where the
production stage transforms the raw materials into the finished goods. While
deterministic, the life expectancy of a pharmaceutical is dependent upon its respective
inventory stage. For example, the raw materials have a shelf life of up to one year while
the finished goods have an unrefrigerated shelf life of less than one day. While the two
stage inventory model expanded the body of knowledge concerning the pharmaceutical
inventory management practices, it does not apply to this study based on its focus of
pharmaceuticals remaining in just one inventory stage (raw materials).

Summary
Chapter 2 provided a review of the relevant literature pertaining to the research
pursuit of determining inventory control policies that provides the optimal mix between
the minimization of inventory cost and the on hand availability of product for potential
customer demand. The literature review was segregated into research studies performed
on the inventory management principles of non-perishable products and perishable
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products. Despite the fact that pharmaceuticals represent the later, the decision to
include a review of non-perishable products was made based on the foundation it
provided for the more complex study of perishable products. The review of inventory
management principles pertaining to perishable products was further segregated into an
overview of fundamental studies focusing on the generalities of perishable items
followed by the extant research conducted on the inventory management of donated
blood units and pharmaceuticals. While the stringent assumptions imposed on the
models reviewed in Chapter 2 do not lend to complete applicability in this particular
study, it provides a foundation from which the methodology will be based. Chapter 3
will detail the methodology used to evaluate the research questions posed in Chapter 1.
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III. Methodology
Overview
The purpose of this chapter is to present the inventory management methodology
used in this study. The chapter begins by describing the data sets that were required to
perform the inventory management methodology, as well as the process used for
collection. Following this, the chapter will outline the steps taken to estimate the
historical inventory positions of the chosen MTF/pharmaceutical combinations, compute
alternative stock levels, and finally to evaluate the results of the alternative stock levels
in terms of cost savings and fill rates.

Data Collection
The basic inventory management methodology used in this study required four
distinct sets of data. Serving as the primary motivation for the study, the first set of data
collected in the effort represented the identification of expired or nearly expired
pharmaceuticals that were turned in by AFMS MTFs during the time period of
September 2012 through September 2014. This data set, provided by the
AFMOA/SGAL office, identified the turn-in of 15,098 unique pharmaceuticals with a
replacement value of $23,168,655.02. Because analysis of 15,098 individual
pharmaceuticals at 81 dispensing locations was unfeasible given the time constraint for
the study, a decision was made to narrow the scope of the study to a more manageable
task.
As a result, a focus was placed on the top 59 pharmaceuticals accounting for the
largest turn-in values amongst CONUS MTFs. Out of the top 59 pharmaceuticals
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identified, 27 pharmaceuticals were further eliminated from the scope of the study based
on War Reserve Material requirements, a discontinuance of patient demand during 2014,
and other disqualifying factors such as the atypical procurement process of influenza
vaccinations. Table 2 displays the 32 pharmaceuticals that were ultimately chosen for
inventory analysis. The study performed inventory analysis on the 32 identified
pharmaceuticals at up to ten MTFs, accounting for the largest portions of the turn-in
value. For example, the top 10 out of 17 MTFs returning Premarin 1.25 mg tablets were
analyzed, whereas all 5 of 5 MTFs returning the Combivent 4 g Inhaler were analyzed.
Table 2: Pharmaceuticals Chosen for Inventory Analysis

Pharmaceuticals
● Abilify 30 mg Tablet

● Levitra 10 mg Tablet

● Acetasol HC Ear Drops

● Mefloquine 250 mg

● Advair 250-50 Diskus

● Nexium DR 40 mg Tablet

● Agrylin 0.5 mg Capsule

● Pancreaze DR 16,800 UU Capsule

● Avonex 30 mcgs

● Premarin 0.3 mg Tablet

● Celebrex 100 mg Capsule

● Premarin 0.625 mg Tablet

● Celebrex 200 mg Capsule

● Premarin 1.25 mg Tablet

● Combivent Respimat Inhaler 4 g

● Prograf 5 mg Capsule

● Epipen 2-pack 0.3 mg Auto-Injector

● Sandostatin Lar 30 mg

● Fosamax Plus D 70 mg--2,800 IU UU

● Spiriva 18 mcg CP-Handihaler

● Fosamax Plus D 70 mg--5,600 IU UU

● Tamiflu 75 mg

● Gleevec 100 mg Tablet

● Tobradex Eye Drops 5 ml

● Gleevec 400 mg Tablet

● Votrient 30 mg

● Glucagon 1 mg

● Vytorin 10-10 mg Tablet

● Januvia 100 mg Tablet

● Zemplar 4 mg

● Lamictal XR 100 mg Tablet

● Zytiga 250 mg Tablet

The second set of data collected represents the historical patient demand for the
MTF/pharmaceutical combinations that were identified for analysis. The data set that
was found to most closely represent the historical patient demand for the identified
MTF/pharmaceutical combinations was the dispensing records from each of the
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respective MTF pharmacies. While this data set does not include any unfilled patient
demand that may have occurred during the time period of 1/1/2012 through 9/19/2014, it
is substantially representative of the overall patient demand. The MTF pharmaceutical
dispensing records were provided by the 711th Human Performance Wing through an ad
hoc query within the Military Health System Management Analysis and Reporting Tool
(M2).
The third set of data collected for the study represents the procurement of the
identified pharmaceuticals from the PPV. This recorded activity signifies the respective
MTF pharmacies receiving a resupply of stock to counterbalance previous patient
disbursements of the pharmaceuticals being studied. This data set was then converted to
match the units of supply found within the patient demand data. For example, one bottle
of the Celebrex 100 mg pharmaceutical was converted to represent the 500 tablets
contained within the PPV supplied bottle. The PPV sales of the identified
pharmaceuticals was provided by the AFMOA/SGAL office through an ad hoc query
within the DMLSS system.
The fourth and final data set that was required to be collected for the inventory
analysis study was the suggested stock levels for the MTF/pharmaceutical combinations
as found in the DMLSS CAIM module. These suggested stock levels were sought as an
estimation of the 1/1/2012 beginning inventory positions in lieu of the actual beginning
inventory position not being available for use in this study. The use of the suggested
stock levels was chosen as a conservative approach based on the likelihood that it
understates the actual beginning inventory positions found on 1/1/2012. Therefore, the
suggested stock levels were used as the beginning 1/1/2012 inventory position unless it
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was discovered to be insufficient in providing estimated inventory positions that did not
fall below zero during the time frame of the study. Inventory positions falling below
zero, signifying a stockout, were not permitted to occur in the estimated timeline of
inventory positions because the data set representing patient demand included only
demand that was filled. The suggested inventory stock level data set was also provided
by the AFMOA/SGAL office through an ad hoc query of the DMLSS system.

Estimation of Historical Inventory Positions
The first step required to perform the cost savings comparison analysis was to
determine the existing inventory state upon which a comparison was to be drawn from.
As previously discussed, daily inventory positions for the MTF/pharmaceutical
combinations were not available for use in the study. Therefore, an estimation of the
historical inventory positions were drawn in accordance with the data that was made
available for the study. The calculations found in Equation 2 were used to estimate the
historical daily inventory positions of the respective MTF/pharmaceutical combinations.
It should be noted that the pharmaceutical returns data used in Equation 2 begins
in September 2012 and not 1/1/2012. This is based on the idea that the daily inventory
position estimates begin on 1/1/2012 with fresh stock that would not be returned to the
reverse logistics vendor during the early portion of the study’s timeline. Occurrences in
September 2012 represent a realistic time frame upon which unused stock from the start
of the timeline would be nearing or past expiration and therefore warrant inventory
return actions. Additionally, the number of units procured from the PPV is represented
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by the previous duty day’s order request for the respective pharmaceutical. This is based
on the PPV’s 24 hour delivery lead time that was previously discussed in Chapter 1.
Ii = (Iі-1 + P) – (D + R)

(2)

Where
I = Inventory Position
P = Number of Units Procured from the PPV
D = Number of Units Demanded
R = Number of Units Returned
After the estimated daily inventory position for days 1/1/2012 through 9/19/2014
were calculated, an average inventory position was calculated. Figure 4 displays a
graphical representation of the estimated daily inventory position timeline for Premarin
0.625 mg at Altus AFB.

Figure 4: Daily Inventory Position Timeline for Premarin 0.625 mg at Altus AFB
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Calculation of an Alternative Order-Up-To Stock Level
The next phase of the methodology is the calculation of an alternative stock level
for the respective MTF/pharmaceutical combination. Guided by the study’s research
questions, the primary objectives in determining an alternative stock level is that it
achieves expiration and on-hand inventory savings for the MTF, while limiting the
number of potential stockout occurrences that are typically associated with lower levels
of stock. Based on these objectives, Equations 3 through 5 were chosen to generate an
appropriate pharmaceutical stock level.
S = LTD + Isafety

(3)

Where
S = Order-Up-To Stock Level
LTD = Average Lead Time Demand
Isafety = Safety Stock
LTD = LR

(4)

Where
L = Average Replenishment Lead Time
R = Average Demand Rate (Mean)

Where

Isafety = t�(𝐿 × 𝜎𝑅2 ) + (𝑅 2 × 𝜎𝐿2 )
t = Service Level Factor
𝜎𝑅2 = Variance of Demand

𝜎𝐿2 = Variance of Lead Time
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(5)

Based on the assumption that the average delivery lead time is fixed at one day
(24 hours) with a lead time variance of zero, the safety stock calculation seen in
Equation 5 is reduced to the desired service level factor multiplied by the standard
deviation of demand for the purposes of this study. The Type 2 service level factor
component of the equation is represented by the t statistic that corresponds to the desired
fill rate (Shivsharan, 2012:6). The t statistic was chosen over the more commonly used z
statistic based on the fact that a significant number of the MTF/pharmaceutical
combinations analyzed in this study possess less than 30 separate days of product
demand greater than zero. Additionally, the choice of the t statistic errs on the side of
caution by providing a more conservative approach. This is based on the fact that it
provides a slightly higher calculation of safety stock for those pharmaceuticals
possessing 30 or more separate days of product demand greater than zero.
As evidenced by the use of the t statistic, Equation 5 assumes a normal or nearly
normal distribution of demand. The use of this equation with the normality assumption
is common practice within industry, despite the fact that the actual distribution of
demand rarely follows such a distribution. This common disregard towards the likely
violation of the normality assumption is typically considered to be acceptable based on
the argument that a more complicated yet accurate representation of the demand during
lead time may be ineffectual because its gain in precision is comparatively small (Silver
& Peterson, 1985:289). Based on this argument and its common use within industry, the
use of Equation 5 with an assumed normal distribution of demand is justified despite the
likely violation of the assumption.
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The calculations captured in Equations 3 through 5 are applied to the respective
patient demand data for the two year time period of 1/1/2012 through 12/31/2013. Days
that generated zero demand are eliminated from the calculations based on the fact that
the service level factor represents the pharmaceutical fill rates. Because fill rates are not
computed on days with zero demand, the decision to remove these days from the orderup-to stock level calculation is valid. Table 3 displays an example of the calculations
performed in determining the appropriate order-up-to stock level for the 200 mg variant
of the Celebrex pharmaceutical at Goodfellow AFB. In this example, the order-up-to
level is calculated to be 825.363 tablets. However, this value is rounded up to the
nearest unit of sale from the PPV (bottle of 500 tablets).
Table 3: Order-Up-To Level Calculation for Celebrex 200 mg at Goodfellow AFB

Goodfellow AFB--Celebrex 200 mg
Calculation
Days w/ Demand > 0
L
R
LTD
σR
T-statistic (99.9%)
Isafety
Order-Up-To Level (S)
S (Rounded)

Value
Units
246
days
1
day
267.862
tablets
267.862
tablets
178.467
tablets
3.123828683
557.501
tablets
825.363
tablets
1,000
tablets

Evaluation of the Alternative Stock Level
After the alternative order-up-to stock levels for each MTF/pharmaceutical
combination has been calculated, the final phase of the study’s methodology is to
evaluate it in terms of potential cost savings and pharmaceutical fill rates. This
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evaluation is performed by testing the performance of the revised stock levels in
response to the MTF/pharmaceutical’s historical demand over the time period of 1/1/14
through 9/19/14. In this testing phase, the ending daily inventory position is calculated
in the same manner as stated in Equation 1. Additionally, it is assumed that the MTF
operates a (R, S) inventory control policy where inventory positions are reviewed at the
end of each duty day. If during the review it is found that a respective pharmaceutical’s
inventory position has fallen below the alternative order-up-to stock level, an order is
placed through the PPV that day with a delivery occurring the following morning of a
duty day. The PPV order will be placed for the quantity that is necessary to bring the
following duty day’s beginning inventory position (after the morning PPV delivery) to a
quantity that meets the alternative order-up-to stock level. Figure 5 provides a graphical
illustration of the daily inventory positions for the Combivent 4g pharmaceutical at
Shaw AFB, utilizing the calculated alternative order-up-to stock level of 12 units.

Figure 5: Example of Inventory Position Using the Alternative Stock Level
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The next step in the evaluation process is to determine the Inventory Turnover
(ITO) rates that the alternative order-up-to stock levels would have provided in the time
period between 1/1/2014 and 9/19/2014. The calculated ITO rates are then used as an
indicator for estimating the potential amount of inventory that would exceed its
expiration date of clinical effectiveness under the revised inventory control policy. As
previously discussed in Chapter 1, a conservative approach assumption is made for the
study to apply a six month lifespan of clinical effectiveness for all pharmaceuticals
procured through the PPV Generation III contract. Based on this assumption, it can be
reasoned that MTF/pharmaceutical combinations exhibiting an annual ITO of two or
more will not require any reverse logistics returns for reasons of expiration. Equation 6
provides the procedure for calculating the ITO rate for the time period in question.
ITO =

𝐴𝑣𝑒𝑟𝑎𝑔𝑒 𝐼𝑛𝑣𝑒𝑛𝑡𝑜𝑟𝑦 𝑉𝑎𝑙𝑢𝑒 ($)
𝐶𝑜𝑠𝑡 𝑜𝑓 𝐺𝑜𝑜𝑑𝑠 𝑆𝑜𝑙𝑑 ($)

(6)

The components of Equation 6 are quite easily found. Average Inventory Value
is simply the unit cost multiplied by the average inventory position, whereas the Cost of
Goods Sold is simply the summation of the number of pharmaceutical units dispensed to
patients during the time period in question multiplied by the unit cost. Because the
evaluation time period does not cover an entire year, the calculated ITR must be
converted into an annual ITO rate. The time period of 1/1/2014 through 9/19/2014
covers 262 of the total 365 days in the year, or approximately 0.717808 years. Based on
this, the ITO rates covering the time periods of 1/1/2014 through 9/19/2014 can be
easily converted to an annual ITO rate by dividing it by 0.717808.
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The next step in the evaluation process of the study’s methodology is to estimate
the annual expiration savings for MTF/pharmaceutical combinations if the alternative
order-up-to stock levels generated an annual ITO that exceeded two turns. For those
MTF/pharmaceutical combinations with an annual ITO exceeding a value of two, the
estimated annual savings from a pharmaceutical perishability is calculated by simply
dividing the respective combination’s actual return value by two. The respective
combination’s actual return value is divided by two based on the fact that the expired
returns data set spanned 24 months from the 9/17/2012 through 9/16/2014.
In addition to the potential savings related to the avoidance of pharmaceutical
perishability, the alternative order-up-to stock levels also provide savings potential that
is realized with a reduction of on-hand stock inventories. While the estimated expiration
savings has the potential to be perpetually realized on an annual basis, a reduction in onhand stock inventories realizes a one time savings. Equation 7 displays the calculations
used to estimate the potential on-hand inventory reduction savings from adopting the
alternative order-up-to stock level. It should be noted that the value used for P is the
average of daily inventory positions that were estimated through the calculation of
Equation 2.

Where

O = C × (P – S)

O = On-hand Inventory Savings
C = Unit Cost of the Pharmaceutical
P = Average Historical Inventory Position
S = Alternate Order-Up-To Stock Level
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(7)

While potential savings from the avoidance of expired pharmaceutical stock and
on-hand stock reductions would be very appealing to DoD financial decision makers, the
realization of these potential savings would be considered impractical if it resulted in a
significant increase in pharmaceutical stockouts. Therefore, the final calculation
performed in this study’s methodology is that of a fill rate. The fill rate is calculated by
simply dividing the number of patient prescriptions that were filled by the total number
of prescription demands placed by the patient for a given pharmaceutical. For example,
the pharmacy at Holloman AFB would have been able to fill 1,508 out of 1,512 requests
for Nexium 40 mg tablets during the time period of 1/1/14 through 9/19/2014 if they
operated under the alternative order-up-to stock level of 2,070 tablets. Therefore, the
pharmaceutical fill rate for Nexium at Holloman AFB was 1,508 divided by 1,512, or
99.74%. It should also be pointed out that the four stockouts that would occur for
Nexium at Holloman AFB could be filled during the following duty day based on the
one day delivery of the PPV.

Summary
Chapter 3 provided a description of the methodology used to answer the research
questions of this study. The methodology began through the collection of four distinct
data sets. The patient demand, pharmaceutical vendor sales records, pharmaceutical
returns and DMLSS CAIM suggested stock levels were all utilized for subsequent steps
in the study’s methodology. The pharmaceutical returns data was initially used to focus
the scope of the study into a manageable undertaking. A combination of all four data
sets were used to establish an estimated timeline of daily inventory positions from the
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time period of 1/1/2012 through 9/19/2014. This estimated timeline of daily inventory
positions provided a historical approximation of the respective MTF/pharmaceutical’s
inventory state. The patient demand data from 1/1/2012 through 12/31/2013 was later
used to calculate an alternative order-up-to stock level for each of the
MTF/pharmaceutical combinations. The final step of the study’s methodology was
performed when the alternate order-up-to stock levels were evaluated in terms of cost
savings and fill rates, with respect to the patient demand data from the time period of
1/1/2014 through 9/19/2014.
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IV. Results and Analysis
Chapter Overview
This chapter summarizes the results derived from the methodology found in
Chapter 3. In addition to summarizing the bottom line results of the overall study, this
chapter will provide in depth analysis on a sampling of the 173 MTF/pharmaceutical
combinations studied. The first MTF/pharmaceutical chosen for analysis provides
opportunity for significant cost savings while also maintaining a 100 percent fill rate
given the use of the calculated alternative order-up-to stock level. The second
combination chosen for analysis provides an opportunity for moderate cost savings
while also delivering a nearly perfect fill rate. The third MTF/pharmaceutical chosen for
analysis provides a modest potential for cost savings while also delivering one of the
lowest fill rates found in the study. This chapter will also provide insight into the
MTF/pharmaceutical combinations that were found to exhibit turnover rates that fell
below 2.

Travis AFB—Fosamax D 70 mg 5,600 IU
The examination of the Fosamax D 70 mg 5,600 IU pharmaceutical at Travis
AFB revealed a substantial opportunity for cost savings. Figure 6 displays the
calculated estimate of the MTF/pharmaceutical’s daily inventory position over the time
period of 1/1/2012 through 9/19/2014. The starting inventory position of 1/1/2012 is
represented by the DMLSS CAIM suggested stock level of 94 packages containing four
tablets each (376 tablets). As a result of a large number of purchases from the PPV in
January and February 2012, the daily inventory position of the MTF/pharmaceutical
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combination quickly escalated to approximately 1,500 tablets. After maintaining this
inventory position for approximately 12 months, the inventory position grew in March
2013 to reach a high of approximately 2,150 tablets. Two sizeable turn-ins of expired
pharmaceuticals in May 2013 reduced the inventory position to a level that fell below
1,000 tablets. Throughout the estimated timeline, the Fosamax D 70 mg 5,600 IU
pharmaceutical at Travis AFB exhibited an average inventory position of 1,420 tablets.

Figure 6: Daily Inventory Position Timeline for Fosamax D 70 mg at Travis AFB

With visual evidence suggesting that an average inventory position of 1,420
tablets of Fosamax D 70 mg was excessive given the daily demand at Travis AFB, the
next step was to calculate an alternative order-up-to stock level. During the time period
of 1/1/2012 through 12/31/2103, there were 333 days where at least one prescription of
Fosamax D 70 mg 5,600 IU was demanded. Applying Equation 3 to the patient demand
of these 333 days, the LTD component was calculated at 16.8048 tablets with the Isafety
component calculated at 27.4 tablets. The addition of these two components produces
the order-up-to stock level to a value of 44.2049 tablets. Based on the Fosamax D 70
mg 5,600 IU pharmaceutical being sold in packages of 4 tablets, the order-up-to stock
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level is rounded up to 48 tablets. Table 4 displays a summary of the order-up-to stock
level calculations for Fosamax D 70 mg at Travis AFB.
Table 4: Order-Up-To Level Calculation for Fosamax D 70 mg at Travis AFB

Travis AFB--Fosamax D 70 mg 5,600 IU
Calculation
Days w/ Demand > 0
L
R
LTD
σR
T-statistic (99.9%)
Isafety
Order-Up-To Level (S)
S (Rounded)

Value
Units
333
days
1
day
16.8048
tablets
16.8048
tablets
8.79627
tablets
3.114960539
27.4
tablets
44.2049
tablets
48
tablets

The calculated alternative order-up-to stock level of 48 tablets was then applied to
the patient demand during the time period of 1/1/2014 through 9/19/2014 and evaluated
in terms of potential cost savings and fill rate. Figure 7 displays the daily inventory
position for Fosamax D 70 mg 5,600 IU at Travis AFB, given the use of the (R, S)
inventory control policy with an order-up-to stock level of 48 tablets.

Figure 7: Inventory Position Timeline for Fosamax D 70 mg at Travis AFB Using the Alternative
Order-Up-To Stock Level in a (R, S) Inventory Control Policy
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The alternative order-up-to stock level provided an annual ITO rate of 33.09
times. Because the ITO rate exceeded a minimum of 2 turns, an annual savings from
expired Fosamax D 70 mg 5,600 IU at Travis AFB was estimated at $8,370.18. In
addition to this annual savings, an estimated one time savings of $18,863.53 would be
achieved by reducing the average inventory position of 1,420 tablets down to 48 tablets.
In spite of the substantial inventory reduction, the Travis pharmacy would have been
capable of filling all 98 of the prescription demands it experienced in the time period of
1/1/2014 through 9/19/2014. Table 5 provides a summary of the results found when
applying the alternative order-up-to stock level of 48 Fosamax D 70 mg 5,600 IU tablets
at Travis AFB.
Table 5: Evaluation Results of the Alternative Order-Up-To Stock Level for
Fosamax D 70 mg 5,600 IU at Travis AFB

Travis AFB--Fosamax D 70 mg 5,600 IU
Measurement
Inventory Turnover Rate
Annual Expiration Savings
On-Hand Stock Savings
Prescriptions Requested
Prescriptions Filled
Fill Rate

Results
33.09
$8,370.18
$18,863.53
98
98
100%

Wright Patterson AFB—Advair 250-50 Diskus
The examination of the Advair 250-50 Diskus pharmaceutical at Wright Patterson
AFB revealed a moderate opportunity for cost savings. Figure 8 displays the calculated
estimate of the MTF/pharmaceutical’s daily inventory position over the time period of
1/1/2012 through 9/19/2014. The starting inventory position of 1/1/2012 is represented
by the DMLSS CAIM suggested stock level of 9,804 individual diskus. With a few
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fleeting exceptions, the inventory position of Advair 250-50 Diskus at Wright Patterson
was maintained within a range of 10,000 and 20,000 diskus during the time period of
January 2012 through September 2013 On 9/17/2012, the Wright Patterson AFB
pharmacy recorded a substantial turn-in of 6,000 expired Advair 250-50 diskus. A
major purchase through the PPV on 10/16/2012 resulted in the inventory position
peaking at just above 30,000 diskus before it quickly returned back into the 12,000 to
18,000 diskus range for the next 11 months. During September 2013 through August
2014, the inventory position once again expanded into a range between 21,000 and
25,000 diskus. From August 2014 through the end of the timeline, the inventory
position declined and fell to a low of 7,824 diskus. Throughout the estimated timeline of
1/1/2012 through 9/19/2014, the Advair 250-50 pharmaceutical at Wright Patterson AFB
exhibited an average inventory position of 17,354 diskus.

Figure 8: Daily Inventory Position Timeline for Advair 250-50 at Wright Patterson
AFB (Historical Estimation)
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With visual evidence suggesting that an average inventory position of 17,354
diskus of Advair 250-50 was excessive given the daily demand at Wright Patterson
AFB, the next step was to calculate an alternative order-up-to stock level. During the
time period of 1/1/2012 through 12/31/2103, there were 688 days where at least one
prescription of Advair 250-50 was demanded at Wright Patterson AFB. Applying
Equation 3 to the patient demand of these 688 days, the LTD component was calculated
at 1,070.15 diskus with the Isafety component calculated at 1,840.25 diskus. The addition
of these two components produces the order-up-to stock level to a value of 2,910.40
diskus. Because it is impossible to have an order-up-to stock level of 2,910.40 diskus,
the value was rounded to the nearest unit of sale. Based on the Advair 250-50
pharmaceutical being sold in cartons of 60 diskus, the order-up-to stock level is rounded
up to 2,940 diskus. Table 6 displays a summary of the order-up-to stock level
calculations for Advair 250-50 at Wright Patterson AFB.
Table 6: Order-Up-To Level Calculation for Advair 250-50 at Wright Patterson
AFB

Wright Patterson AFB--Advair 250-50
Calculation
Days w/ Demand > 0
L
R
LTD

Value
688
1
1070.15
1070.145

σR

Units
days
day
diskus
diskus

T-statistic (99.9%)

diskus
593.2213
3.102138

Isafety

1840.25

diskus

Order-Up-To Level (S)
S (Rounded)

2910.4
2,940

diskus
diskus
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The calculated alternative order-up-to stock level of 2,940 diskus was then
applied to the patient demand during the time period of 1/1/2014 through 9/19/2014 and
evaluated in terms of potential cost savings and fill rate. Figure 9 displays the daily
inventory position for Advair 250-50 at Wright Patterson AFB, given the use of the (R,
S) inventory control policy with an order-up-to stock level of 2,940 diskus.

Figure 9: Inventory Position Timeline for Advair 250-50 at Wright Patterson AFB
Using the Alternative Order-Up-To Stock Level in a (R, S) Inventory Control
Policy
The alternative order-up-to stock level provided an annual ITO rate of 113.53
turns. Because the annual ITO rate far exceeded the threshold of 2 turns, an annual
savings from expired Advair 250-50 at Wright Patterson AFB was estimated at
$4,605.94. In addition to this annual savings, an estimated one time savings of
$21,553.69 would be achieved by reducing the average inventory position of 17,354
discus down to 2,940 diskus. In spite of the substantial inventory reduction, the Wright
Patterson pharmacy would have been capable of filling 1,436 of the total 1,437
prescription demands it experienced in the time period of 1/1/2014 through 9/19/2014.
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While not a perfect fill rate, this resulted in the very high fill rate of 99.93%. Table 7
provides a summary of the results found when applying the alternative order-up-to stock
level of 2,940 Advair 250-50 diskus at Wright Patterson AFB.
Table 7: Evaluation Results of the Alternative Order-Up-To Stock Level for
Advair 250-50 at Wright Patterson AFB

Wright Patterson AFB—Advair 250-50
Measurement
Inventory Turnover Rate
Annual Expiration Savings
On-Hand Stock Savings
Prescriptions Requested
Prescriptions Filled
Fill Rate

Results
113.53
$4,605.94
$21,553.69
1,437
1,436
99.93%

Sheppard AFB—Tamiflu 75 mg
The examination of the Tamiflu 75 mg pharmaceutical at Sheppard AFB revealed
a comparatively modest opportunity for cost savings. Figure 10 displays the calculated
estimate of the MTF/pharmaceutical combination’s daily inventory position over the
time period of 1/1/2012 through 9/19/2014. The Sheppard AFB/Tamiflu 75 mg
combination is one of the examples where the DMLSS CAIM suggested stock level was
not sufficient enough to prevent stockouts in the historical estimation. Based on this, a
starting inventory position of 960 tablets was chosen based on it representing the lowest
stock level that prevented any stockouts from occurring in the historical estimation.
With the exception two major transactions, there was very little activity that
occurred with respect to the Tamiflu 75 mg pharmaceutical at Sheppard AFB over the
first two years of the estimated historical timeline. The two major transactions that took
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place during those first two years was a purchase from the PPV in the amount of 480
tablets on August 27, 2012 followed by a return 460 tablets of the Tamiflu 75 mg
pharmaceutical on 3/14/2014. However, the third year of the timeline experienced a
larger amount of activity, temporarily bringing the inventory position down to zero.
Throughout the estimated timeline of 1/1/2012 through 9/19/2014, the Tamiflu 75 mg
pharmaceutical at Sheppard AFB exhibited an average inventory position of 698 tablets.

Figure 10: Daily Inventory Position Timeline for Tamiflu 75 mg at Sheppard AFB (Historical
Estimation)

The next step in the study’s methodology was to calculate an alternate order-up-to
stock level. During the time period of 1/1/2012 through 12/31/2103, there were 54 days
where at least one prescription of Tamiflu 75 mg was demanded. Applying Equation 3
to the patient demand of these 54 days, the LTD component was calculated at 16.48148
tablets with the Isafety component calculated at 32.3018 tablets. The addition of these two
components produces the order-up-to stock level to a value of 48.7833 tablets. Based on
the Tamiflu 75 mg pharmaceutical being sold in packages of 10 tablets, the order-up-to
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stock level was rounded up to 50 tablets. Table 8 displays a summary of the order-up-to
stock level calculations for Tamiflu 75 mg at Sheppard AFB.
Table 8: Order-Up-To Level Calculation for Tamiflu 75 mg at Sheppard AFB

Sheppard AFB--Tamiflu 75 mg
Calculation
Days w/ Demand > 0
L
R
LTD

Value
54
1
16.48148
16.48148

Units
days
day
tablets
tablets

σR

9.93515

tablets

T-statistic (99.9%)

3.251268

Isafety

32.3018

tablets

Order-Up-To Level (S)
S (Rounded)

48.7833
50

tablets
tablets

The calculated alternative order-up-to stock level of 50 tablets was then applied to
the patient demand during the time period of 1/1/2014 through 9/19/2014 and evaluated
in terms of potential cost savings and fill rate. Figure 11 displays the daily inventory
position for Tamiflu 70 mg at Sheppard AFB, given the use of the (R, S) inventory
control policy with an order-up-to stock level of 50 tablets.

Looking at Figure 11, it is

quite apparent that the calculated alternative order-up-to stock level of 50 was not
substantial enough to prevent a significant number of stockouts that would have
occurred at the beginning of the 2014 calendar year. This is primarily due to the lower
patient demand for Tamiflu 75 mg in 2012 and 2013 not providing a suitable prediction
basis for the larger amount of patient demand that occurred in 2014.
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Figure 11: Inventory Position Timeline for Tamiflu 70 mg at Sheppard AFB Using the Alternative
Order-Up-To Stock Level in a (R, S) Inventory Control Policy

Despite the apparent failures of the calculated alternative order-up-to stock level
for this MTF/pharmaceutical combination, the evaluation process within the
methodology was pursued. The alternative order-up-to stock level provided an annual
ITO rate of 43.19 times. Because the ITO rate far exceeded the threshold of 2 turns, an
annual savings from expired Tamiflu 75 mg at Sheppard AFB was estimated at $331.81.
In addition to this annual savings, an estimated one time savings of $1,401.89 would be
achieved by reducing the average inventory position of 698 tablets down to 50 tablets.
As was expected, the Sheppard pharmacy would have been capable of filling only 114 of
the total 155 prescription demands it experienced in the time period of 1/1/2014 through
9/19/2014 given an order-up-to stock level of 50 tablets. This results in a very poor fill
rate of 73.55%. Table 9 provides a summary of the results found when applying the
alternative order-up-to stock level of 50 Tamiflu 70 mg tablets at Sheppard AFB.
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Table 9: Evaluation Results of the Alternative Order-Up-To Stock Level for Tamiflu 75 mg at
Sheppard AFB

Sheppard AFB—Tamiflu 75 mg
Measurement
Inventory Turnover Rate
Annual Expiration Savings
On-Hand Stock Savings
Prescriptions Requested
Prescriptions Filled
Fill Rate

Results
43.19
$331.81
$1,401.89
155
114
73.55%

MTF/Pharmaceutical Combinations with Low Annual ITO Rates
Out of the total 173 MTF/pharmaceutical combinations analyzed in the study, 18
of the combinations exhibited Annual ITO rates below 2 turns during the time period of
1/1/2014 through 9/19/2014 given their alternative order-up-to stock levels. Table 10
displays these 18 combinations with the corresponding annual ITO rates.
Table 10: MTF/Pharmaceutical Combinations with Annual ITO Rates Below 2

Pharmaceutical
Acetasol HC
Avonex 30 mg
Fosamax D 70-2,800
Fosamax D 70-5,600
Fosamax D 70-5,600
Gleevec 400 mg
Gleevec 400 mg
Lamictal 100 mg
Lamictal 100 mg
Lamictal 100 mg
Mefloquine 250 mg
Mefloquine 250 mg
Mefloquine 250 mg
Mefloquine 250 mg
Mefloquine 250 mg
Pancreaze DR
Sandostatin 30 mg
Zemplar 4 mg

Base
Andrews
Lackland
Mt. Home
Kirtland
Maxwell
Keesler
Moody
Andrews
Kirtland
Seymour J.
Hill
Lackland
Little Rock
Offutt
Robins
Andrews
Lackland
Lackland

Avg. OnFill
Hand Savings Requests Stockouts
$3,585.89
$27,362.48
$2,063.39
$4,272.68
$915.42
$14,930.42
$2,585.76
$792.81
$280.00
$24,582.32
$1,805.43
$14,386.76
$355.25
$1,455.25
$1,434.06
$1,784.16
$12,452.74
$10,159.68
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1
2
2
1
1
2
2
4
1
0
3
3
4
3
3
1
2
1

0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

Fill
Rate

Annual
ITO

100%
100%
100%
100%
100%
100%
100%
100%
100%
N/A
100%
100%
100%
100%
100%
100%
100%
100%

1.39
0.76
1.04
0.84
0.22
1.67
1.39
1.28
0.08
0
0.78
0.09
0.82
1.34
0.47
1.25
0.93
1.39

Over the two year time period of September 2012 through September 2014, these
18 MTF/pharmaceutical combinations accounted for $46,441.08 (average annual cost of
$23,220.54) in pharmaceutical returns. Based on their annual ITO rates being below the
threshold of 2 turns per year, there is no way of completely eliminating perishability
costs for these combinations given the calculated order-up-to stock levels. With that
stated, the alternative order-up-to stock levels for these 18 combinations would most
certainly reduce the perishability cost to levels lower than was previously experienced.
In addition a reduction in perishability costs, the use of the calculated order-up-to stock
level would provide a one time on-hand inventory reduction savings of $125,204.50.

Summary
Upon analysis of the 173 MTF/pharmaceutical combinations within the scope of
this study, it was determined the use of an alternative order-up-to stock level in a (R, S)
inventory control policy could save the AFMS a significant amount of money in cost
reductions. Table 11 displays a summary of the results generated by the 155
MTF/pharmaceutical combinations that exhibited an annual ITO that exceeded the 2 turn
threshold. Using the alternative order-up-to stock levels would have provided an
estimated annual perishability cost reduction of $419,504.10.
In addition to the annual perishability cost savings, the study found that the
adoption of the alternative order-up-to stock levels could provide the AFMS with a onetime inventory reduction savings of approximately $1,769,138.82. This figure includes
the 155 MTF/pharmaceutical combinations with annual ITOs above 2 turns, as well as
the 18 combinations with annual ITOs below 2 turns. In spite of the inventory
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reductions that would occur with the use of the alternative order-up-to stock levels in a
(R, S) inventory control policy, the evaluation phase of the methodology determined that
the overall fill rate amongst the studied MTF/pharmaceutical combinations would be
above 99.8%. A breakdown of the individual MTF/pharmaceutical combination results
can be found in Appendix A through AF.
Table 11: Summary of Results by Pharmaceutical

Savings
Pharmaceutical
Abilify 30 mg
Acetasol HC
Advair 250-50
Agrylin 0.5 mg
Avonex 30 mg
Celebrex 100 mg
Celebrex 200 mg
Combivent 4 g
Epipen
Fosamax D 70-2,800
Fosamax D 70-5,600
Gleevec 100 mg
Gleevec 400 mg
Glucagon 1 mg
Januvia 100 mg
Levitra 10 mg
Nexium 40 mg
Pancreaze 16,800 IU
Premarin 0.3mg
Premarin 0.625 mg
Premarin 1.25 mg
Prograf 5mg
Sandostatin 30 mg
Spiriva 18 mcg
Tamiflu 75 mg
Tobradex 5 ml
Votrient 30 mg
Vytorin 10 mg
Zytiga 250 mg

Annual
Expiration
$30,618.84
$13,465.13
$11,423.82
$15,929.75
$10,118.42
$5,917.95
$14,917.89
$12,055.01
$19,091.93
$15,795.77
$27,674.01
$6,838.95
$19,280.18
$14,497.62
$3,760.20
$10,976.00
$23,078.00
$6,360.41
$16,773.20
$16,276.67
$29,810.28
$21,243.69
$3,913.85
$9,673.62
$13,032.38
$8,678.88
$17,207.21
$8,286.93
$12,807.59

Totals

$419,504.10

1/1/2014 - 9/19/2014

Average
On-Hand
$69,790.13
$23,115.46
$74,371.09
$18,472.50
$47,398.02
$94,270.77
$66,560.13
$30,953.02
$133,359.48
$24,606.95
$57,703.05
$21,481.59
$14,914.51
$79,772.01
$67,138.54
$70,597.37
$141,716.94
$38,323.89
$87,245.01
$76,003.38
$87,867.18
$58,137.21
$11,269.88
$73,976.60
$32,206.87
$17,024.00
$10,357.55
$60,222.12
$55,079.07
$1,643,934.32
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Fill Rate
Requests
72
95
4,125
8
32
1,784
320
512
2,581
541
285
18
41
928
2,871
33
37,901
113
1,143
1,265
498
14
9
5,601
785
45
4
541
28

Stockouts
1
0
0
0
0
0
0
3
13
3
2
0
0
6
4
0
4
1
0
0
0
0
0
11
63
0
0
0
3

Fill Rate
98.61%
100.00%
100.00%
100.00%
100.00%
100.00%
100.00%
99.41%
99.50%
99.45%
99.30%
100.00%
100.00%
99.35%
99.86%
100.00%
99.99%
99.12%
100.00%
100.00%
100.00%
100.00%
100.00%
99.80%
91.97%
100.00%
100.00%
100.00%
89.29%

62,193

114

99.82%

In the case of a MTF returning a pharmaceutical to the reverse logistics vendor
prior to its expiration date, the MTF receives a credit to be used in future procurement of
other pharmaceuticals through the PPV. The amount of the credit is not a static figure
and depends on factors such as the remaining lifespan of the pharmaceutical and the
manufacturer’s unique return policy. Despite the varying credit amounts received by
MTF, a representative from the AFMOA/SGAL office provided an estimate of
approximately 40% of the returned pharmaceutical’s retail value. In response to the
shifting credit returns rate experienced by MTFs, Table 12 displays the effective
perishability cost savings of the studied MTF/pharmaceutical combinations given a
credit returns range of 30 through 50 percent.
Table 12: Sensitivity Table for Effective Perishability Cost Savings

Credit %

Effective Perishability
Cost Savings

30
35
40
45
50

$293,652.87
$272,677.67
$251,702.46
$230,727.26
$209,752.05

Table 12 extends the benefit of doubt and treats all returns of the studied
combinations as possessing a remaining lifespan of clinical effectiveness upon the date
of return and therefore triggering a credit to be issued. Although unlikely that each and
every one of the studied returns had not reached the end of its expiration date, the AFMS
would achieve an effective perishability cost savings of approximately $209,752.05 on
the low-end and $293,652.87 on the high-end each year by using the alternative orderup-to stock level for the studied MTF/pharmaceutical combinations. Assuming that the
AFMOA/SGAL office estimate of a credit equaling 40 percent of the pharmaceutical’s
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retail value, the AFMS would achieve a perishability cost savings of approximately
$251,702.46 each year using the methodology found in Chapter 3.
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V. Conclusions and Recommendations
Overview
The chapter begins by summarizing the study by answering the research questions
that were posed in Chapter 1 and concludes with recommendations for action and future
research.

Summary of the Research and Answers to the Research Questions
This study analyzed a total of 173 MTF/pharmaceutical combinations with respect
to their historical inventory practices over the time period of 1/1/2012 through
9/19/2014. At the conclusion of the analysis, it was determined that the respective MTF
pharmacies were holding an excessive amount of pharmaceutical stock, given the
contractual performance service agreements they held with their respective PPV. The
unique aspect of this study is that it was the first known to apply patient demand to the
pharmaceutical inventory analysis, whereas previous efforts utilized prior PPV sales as a
substitute for the demand function.
The research effort applied a basic inventory management calculation to the patient
pharmaceutical demand data as a means to determine an alternative order-up-to stock
level for each of the respective MTF/pharmaceutical combinations. The alternative
order-up-to stock levels were then evaluated against the 1/1/2014 through 9/19/2014
patient demand data in terms of cost savings and fill rates. The ensuing estimated cost
savings and fill rate results were then used to answer the three research questions posed
in the study.

57

1. What cost savings can the AFMS realize in terms of reducing the amount of
expired or near expired pharmaceutical returns, given the application of an
inventory control system that utilizes adjusted order-up-to stock level quantities?
Out of the 155 MTF/pharmaceutical combinations studied that exhibited an annual
ITO rate exceeding the 2 turn threshold, it is estimated that the AFMS could save
$419,504.10 annually. Because the AFMS receives credits for the return of
pharmaceuticals with a remaining lifespan, the effective savings rate realized by the
AFMS would be less than the $419,504.10. Using a conservative approach and
assuming the unlikely event that all of the returns possessed a lifespan of clinical
usefulness upon the return date, the effective savings for the 155 MTF/pharmaceuticals
combinations ranged from $209,752.05 to $293,652.87.
2. What cost savings can the AFMS realize in terms of reducing on-hand
pharmaceutical stock, given the application of an inventory control system that
utilizes adjusted order-up-to stock level quantities?
Out of the 173 MTF/pharmaceutical combinations analyzed in this study, it was
estimated that the use of the (R, S) inventory control policy with the calculated
alternative order-up-to stock levels would provide the AFMS with a one time inventory
reduction savings of $1,769,138.82.
3. What impact will the proposed inventory control system have on pharmaceutical
fill rates?
Aggregated across the 173 MTF/pharmaceutical combinations analyzed in this
study, it was determined that the overall fill rate would have exceeded 99.82 percent. In
other terms, the collection of MTFs studied would have been unable to fill 114 of the
62,193 prescriptions that were demanded during the time period of 1/1/2014 through
9/19/2014. While the aggregated fill rate across all of the studied combinations is
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reasonably high given the cost savings trade-off, there were two pharmaceuticals that
exhibited undesirable fill rates, namely Tamiflu 75 mg and Zytiga 250 mg.
The primary cause of the undesirable fill rates amongst these two pharmaceuticals is
that the patient demand pattern changed considerably from the data used to calculate the
alternative order-up-to stock level (1/1/2012 through 12/31/2013) to the data used to
evaluate the alternative order-up-to stock level (1/1/2014 through 9/19/2014). Because
it is extremely difficult for statistical analysis to forecast extreme shifts in demand, the
AFMS would continue rely on the expertise and experience of the clinical staff to
provide inventory policy recommendations on pharmaceuticals whose demand is
projected to change. For example, the clinical staff may have been alerted to a
heightened flu season in 2014 and therefore made a recommendation for the pharmacy
to modify the calculated order-up-to stock levels accordingly for the Tamiflu 75 mg
pharmaceutical.

Recommendations for Action
Based on the assumption that AFMS leadership regards a 99.82% fill rate as a
palatable trade-off for the cost savings ascertained in this study, it is recommended that a
pilot study be conducted with one or more of the MTF/pharmaceutical combinations
identified in this research effort. Conducting a pilot study on a small scale will allow
AFMS leadership to evaluate the feasibility of implementing the proposed inventory
control policy with a calculated alternative order-up-to stock level using patient demand.
In addition to providing a mechanism for evaluating the inventory control policy’s
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feasibility, a pilot study would allow AFMS leadership to evaluate changes in actual cost
savings, fill rates, and patient satisfaction rates.
A secondary recommendation stemming from this research effort suggests that all
pharmaceuticals exhibiting an annual ITO rate below 2 turns should be evaluated by the
MTF’s clinical staff in terms of approving or disapproving its continuation on the
clinic’s formulary. While there are certainly cases where a pharmaceutical with an
annual ITO rate below 2 turns should be retained on a pharmacy’s formulary (i.e.,
lifesaving pharmaceuticals in an inpatient hospital), there are other cases where the
preservation of a slow-moving pharmaceutical on the MTF formulary is not cost
effective or clinically warranted. Given access to the costs associated with
pharmaceuticals exhibiting low annual ITO rates, the MTF’s clinical staff will be
provided the information necessary to make an appropriate tradeoff decision.

Recommendation for Future Research
Future research related to this study includes:
•

A research effort that calculates the cost savings and fill rates in accordance with
the strict utilization of the DMLSS CAIM suggested stock levels as the alternative
order-up-to stock level in a (R, S) inventory control policy. Comparing these cost
savings and fill rate results to the results of this study would provide insight into
determining if patient demand or previous PPV sales is the better method in
calculating the order-up-to stock level quantities.

•

A pharmaceutical inventory and safety stock analysis that addresses segments of
Air Force medicine that was not covered in this study. Such segments include the
inventory control policies of OCONUS MTFs, influenza vaccinations, and the
pharmaceuticals which are stocked inherently for WRM or Medical CounterChemical, Biological, Radiological, and Nuclear purposes (MC-CBRN) purposes.
o An inventory and safety stock analysis of OCONUS MTFs will require
additional factors to be considered, such as the potential for longer lead
time demands and higher variability in vendor fulfillment rates.
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o An inventory and safety stock analysis on seasonal influenza vaccinations
will need to factor in the nuances of the AFMS’ flu vaccination
procurement process and dissemination. Such nuances include but are
not limited to the small number of orders for comparatively large
quantities and the base’s policy regarding the dissemination of the flu
vaccinations to civilian employees of the base who are not covered by
TRICARE.
o An inventory and safety stock analysis on pharmaceuticals that are
stocked inherently for WRM or MC-CBRN purposes, such as the
Antidote Treatment Nerve Agent Auto-Injector (ATNAA), could be
conducted in search of an inventory control policy that achieves cost
savings over the status quo policies while also ensuring the highest level
of availability as possible.
•

A study that examines the feasibility of implementing an inventory control
system that, like the one proposed in this study, calculates the order-up-to stock
levels in accordance with patient demand. The feasibility study could also
examine the impact that implementing the proposed inventory control policy
would have on pharmacy operations. One impact for analysis is the increase in
order frequency that will occur as a result of implemented the proposed
inventory control policy. From 1/1/2014 through 9/19/2014, the proposed
inventory control policy applied to the 173 MTF/pharmaceutical combinations
would have increased the number of replenishment orders from 4,576 to 12,675.
As an alternative to the implementation of the proposed inventory control policy
being performed by Air Force personnel, a feasibility study concerning a
movement towards a Vendor Managed Inventory (VMI) system for Air Force
pharmaceuticals could be explored.
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Appendix A ― Abilify 30 mg Results

Abilify 30 mg
Savings
Base
Annual Expiration
Average On-Hand
Eglin
$465.98
$819.34
Lackland
$28,709.03
$44,906.12
Luke
$260.90
$9,164.06
Patrick
$258.62
$4,120.99
Peterson
$225.36
$3,536.99
Randolph
$698.97
$7,242.63
Total

$30,618.84

$69,790.13
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1/1/2014 - 9/19/2014
Requests Stockouts Turnover
8
0
3.34
14
0
4.76
13
1
6.69
9
0
5.22
6
0
4.64
22
0
6.24
72
Fill Rate

1
98.61%

Appendix B ― Acetasol HC Results

Acetasol HC
Base
Andrews
Charleston
Lackland
Langley
Luke
Travis
Wright Patterson
Total

Savings
1/1/2014 - 9/19/2014
Annual Expiration Average On-Hand Requests Stockouts Turnover
$0
$3,586
1
0
1.39
$1,426
$1,229
9
0
4.18
$204
$390
7
0
4.88
$2,241
$5,998
9
0
4.18
$2,706
$2,189
19
0
11.61
$4,546
$9,552
32
0
13.1
$2,343
$3,758
19
0
13.23
$13,465

$26,701

63

96
Fill Rate

0
100.00%

Appendix C ― Advair 250-50 Results

Advair 250-50
Base
Holloman
McConnell
McGuire
Robins
Sheppard
Tinker
Vance
Wright Patterson
Total

Savings
Annual Expiration
Average On-Hand
$1,086
$12,709
$543
$596
$1,794
$9,117
$1,077
$5,669
$1,062
$2,186
$897
$18,309
$359
$4,233
$4,606
$21,554
$11,424

$74,371

64

1/1/2014 - 9/19/2014
Requests Stockouts Turnover
338
0
54.74
291
0
60.25
431
5
74.39
451
1
69.66
400
0
69.51
674
0
74.23
103
1
40.09
1437
1
113.53
4125
Fill Rate

8
99.81%

Appendix D ― Agrylin 0.5 mg Results

Agrylin 0.5 mg
Savings
Base
Annual Expiration
Average On-Hand
Lackland
$15,929.75
$18,472.50
Total

$15,929.75

$18,472.50
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1/1/2014 - 9/19/2014
Requests Stockouts Turnover
8
0
3.76
8
Fill Rate

0
100.00%

Appendix E ― Avonex 30 mg Results

Avonex 30 mcgs
Savings
Base
Annual Expiration
Average On-Hand
Andrews
$3,353.16
$29,895.91
Lackland
$0.00
$27,362.48
Travis
$6,765.26
$17,502.11
Total

$10,118.42

$74,760.50
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1/1/2014 - 9/19/2014
Requests Stockouts Turnover
28
0
13.93
2
0
0.76
4
0
2.79
34
Fill Rate

0
100.00%

Appendix F ― Celebrex 100 mg Results

Celebrex 100 mg
Base
Holloman
Maxwell
Sheppard
Tinker
Wright
Patterson
Total

Savings
Annual Expiration Average On-Hand
$1,493.15
$5,291.23
$1,477.73
$4,136.82
$728.66
$25,230.00
$1,108.29
$17,315.63

1/1/2014 - 9/19/2014
Requests Stockouts Turnover
85
0
25.08
212
0
51.47
188
0
31.36
356
0
47.3

$1,110.14

$42,297.09

943

0

$5,917.95

$94,270.77

1784
Fill Rate

0
100.00%
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91.23

Appendix G ― Celebrex 200 mg Results

Celebrex 200 mg
Savings
Base
Annual Expiration Average On-Hand
Goodfellow
$14,917.89
$66,560.13
Total

$14,917.89

$66,560.13
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1/1/2014 - 9/19/2014
Requests Stockouts Turnover
320
0
35.9
320
Fill Rate

0
100.00%

Appendix H ― Combivent 4 gm Results

Combivent 4 gm
Base
Andrews
FE Warren
Goodfellow
Seymour
Johnson
Shaw
Total

Savings
Annual Expiration Average On-Hand
$45.60
$1,627.18
$80.84
$2,239.96
$2,773.41
$1,647.02

1/1/2014 - 9/19/2014
Requests Stockouts Turnover
72
0
24.03
93
1
38.49
64
1
30.45

$8,607.96
$547.20

$22,155.11
$3,283.75

108
175

1
0

$12,055.01

$30,953.02

512
Fill Rate

3
99.41%
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39.78
50.62

Appendix I ― Epipen Results

Epipen
Base
Eglin
FE Warren
Los Angeles
Langley
Luke
Maxwell
Mt. Home
Robins
Tyndall
Total

Savings
Annual Expiration Average On-Hand
$2,800.71
$21,453.32
$1,503.06
$9,647.60
$1,300.94
$615.93
$3,149.87
$17,623.18
$1,922.30
$8,582.42
$2,022.44
$55,888.92
$2,543.64
$1,079.91
$2,353.07
$13,744.01
$1,495.92
$4,724.19
$19,091.93

$133,359.48
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1/1/2014 - 9/19/2014
Requests Stockouts Turnover
546
1
89.58
101
0
34.83
73
0
24.15
651
4
87.87
350
1
70.43
251
5
72.66
84
0
32.74
328
2
83.36
197
0
50.35
2581
Fill Rate

13
99.50%

Appendix J ― Fosamax 70 mg / 2,800 IU Vitamin D Results

Fosamax 70 mg / 2,800 IU Vitamin D
Base
Andrews
Barksdale
Keesler
Los Angeles
Luke
Mt. Home
Patrick
Travis
Tyndall
Total

Savings
Annual Expiration Average On-Hand
$1,433.18
$2,024.63
$3,566.49
$2,297.50
$749.07
$903.71
$1,689.78
$1,531.45
$853.10
$2,063.39
$0.00
$2,063.39
$5,088.11
$12,153.79
$1,186.77
$984.15
$1,229.28
$2,648.33
$15,795.77

$26,670.34
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1/1/2014 - 9/19/2014
Requests Stockouts Turnover
27
0
12.69
22
0
10.22
21
0
14.63
34
0
17.07
2
0
13.06
2
0
1.04
352
0
52.24
20
0
11.94
63
3
29.43
543
Fill Rate

3
99.45%

Appendix K ― Fosamax 70 mg / 5,600 IU Vitamin D Results

Fosamax 70 mg -- 5,600 IU Vitamin D
Savings
Base
Annual Expiration
Average On-Hand
Barksdale
$5,734.20
$3,838.08
Eglin
$1,754.01
$5,982.14
Keesler
$2,649.00
$7,949.72
Kirtland
$0.00
$4,272.68
Langley
$1,621.22
$7,586.95
Little Rock
$1,733.62
$2,239.55
Luke
$1,392.21
$3,393.59
Maxwell
$0.00
$915.42
Offutt
$3,195.48
$6,301.44
Travis
$8,370.18
$18,863.53
Wright Patterson
$1,224.12
$1,548.05
Total

$27,674.02

$62,891.15
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1/1/2014 - 9/19/2014
Requests Stockouts Turnover
4
0
3.34
23
0
13.73
6
0
3.13
1
0
0.84
61
0
22.67
11
0
9.19
8
2
6.08
1
0
0.22
58
0
25.7
98
0
33.09
16
0
7.43
287
Fill Rate

2
99.30%

Appendix L ― Gleevec 100 mg Results

Gleevec 100 mg
Savings
Base Annual Expiration
Average On-Hand
Travis
$6,838.95
$21,481.59

1/1/2014 - 9/19/2014
Requests Stockouts Turnover
18
0
11.26

Total

18
Fill Rate

$6,838.95

$21,481.59

73

0
100.00%

Appendix M ― Gleevec 400 mg Results

Gleevec 400 mg
Savings
Base
Annual Expiration Average On-Hand
Keesler
$0.00
$14,930.42
Moody
$0.00
$2,585.76
Travis
$19,280.18
$14,914.51
Total

$19,280.18

$32,430.69
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1/1/2014 - 9/19/2014
Requests Stockouts Turnover
2
0
1.67
2
0
1.39
41
0
22.12
41
Fill Rate

0
100.00%

Appendix N ― Glucagon 1 mg Results

Glucagon 1 mg
Savings
Base
Annual Expiration Average On-Hand
Buckley
$3,520.38
$4,631.64
Dover
$280.68
$1,479.48
FE Warren
$409.68
$1,046.72
Keesler
$1,082.33
$5,697.52
Lackland
$2,339.90
$6,065.18
Langley
$1,086.92
$1,064.43
Moody
$582.45
$2,151.73
Nellis
$1,433.87
$10,968.92
Travis
$1,962.83
$28,418.93
Wright Patterson
$1,798.61
$18,247.46
Total

$14,497.62

$79,772.01
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1/1/2014 - 9/19/2014
Requests Stockouts Turnover
37
0
15.05
13
0
4.64
30
0
13.23
66
0
26.67
238
2
46.1
53
0
16.02
11
0
4.53
115
0
36.82
161
2
55.03
204
2
57.27
57.27
928
6
Fill Rate
99.35%

Appendix O ― Januvia 100 mg Results

Januvia 100 mg
Savings
Base
Annual Expiration
Average On-Hand
Goodfellow
$1,068.60
$13,702.87
Los Angeles
$89.18
$5,069.19
Malmstrom
$718.28
$2,193.12
Mt Home
$538.71
$2,252.43
Shaw
$896.45
$7,415.23
Travis
$90.44
$25,947.83
Vance
$358.56
$10,557.87
Total

$3,760.20

$67,138.54
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1/1/2014 - 9/19/2014
Requests Stockouts Turnover
180
2
48.99
264
0
72.54
177
0
48.64
190
0
40.19
530
2
78.61
1351
0
103.47
179
0
61.88
2871
Fill Rate

4
99.86%

Appendix P ― Lamictal 100 mg Results

Lamictal 100 mg
Base
Andrews
Kirtland
Seymour J.
Total

Savings
Annual Expiration Average On-Hand
$0.00
$792.81
$0.00
$280.00
$0.00
$24,582.32
$0.00

$25,655.13
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1/1/2014 - 9/19/2014
Requests Stockouts Turnover
4
0
1.28
1
0
0.08
0
0
0
5
Fill Rate

0
100.00%

Appendix Q ― Levitra 10 mg Results

Levitra 10 mg
Savings
Base Annual Expiration Average On-Hand
Travis
$10,976.00
$70,597.37

1/1/2014 - 9/19/2014
Requests Stockouts Turnover
33
0
22.89

Total

33
Fill Rate

$10,976.00

$70,597.37
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0
100.00%

Appendix R ― Mefloquine 250 mg Results

Mefloquine 250 mg
Base
Hill
Lackland
Little Rock
Offutt
Robins
Total

Savings
Annual Expiration Average On-Hand
$0.00
$1,805.43
$0.00
$14,386.76
$0.00
$355.25
$0.00
$1,455.25
$0.00
$1,434.06
$0.00

$19,436.75
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1/1/2014 - 9/19/2014
Requests Stockouts Turnover
3
0
0.78
3
0
0.09
4
0
0.82
3
0
1.34
3
0
0.47
16
Fill Rate

0
100.00%

Appendix S ― Nexium 40 mg Results

Nexium 40 mg
Savings
Base
Annual Expiration Average On-Hand
Goodfellow
$6,971.69
$12,963.57
Hill
$1,477.56
$22,970.60
Holloman
$1,309.68
$5,573.69
Little Rock
$901.76
$1,623.82
MacDill
$4,808.64
$50,876.17
Maxwell
$1,298.52
$5,051.18
Robins
$3,318.87
$12,266.13
Tinker
$1,172.28
$27,828.08
Whiteman
$1,819.01
$2,563.70
Total

$23,078.00

$141,716.94
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1/1/2014 - 9/19/2014
Requests Stockouts Turnover
1235
0
77.66
4557
0
121.09
1512
4
93.7
4383
0
129.35
7985
0
111.64
5765
0
129.32
5096
0
114.66
5412
0
106.96
1956
0
101.87
37,901
Fill Rate

4
99.99%

Appendix T ― Pancreaze 16,800 IU Results

Pancreaze 16,800 UU
Savings
Base
Annual Expiration
Average On-Hand
Andrews
$0.00
$1,784.16
Eglin
$1,356.75
$2,970.16
Keesler
$1,389.83
$3,936.63
Lackland
$1,714.55
$16,374.11
Maxwell
$268.32
$2,143.96
Travis
$1,630.97
$12,899.03
Total

$6,360.41

$40,108.05
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1/1/2014 - 9/19/2014
Requests Stockouts Turnover
1
0
1.25
58
0
8.81
6
0
2.51
21
1
12.96
21
0
11.02
7
0
3.34
114
Fill Rate

1
99.12%

Appendix U ― Premarin 0.3 mg Results

Premarin 0.3 mg
Base
Barksdale
Beale
Cannon
Langley
Little Rock
Luke
Scott
Seymour
Shaw
Total

Savings
Annual Expiration
Average On-Hand
$3,826.68
$10,046.01
$1,061.51
$2,556.18
$969.54
$2,832.62
$2,460.99
$15,722.26
$1,932.60
$3,795.10
$2,929.55
$20,548.14
$1,452.05
$5,670.29
$726.02
$12,117.36
$1,414.28
$13,957.05
$16,773.20

$87,245.01
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1/1/2014 - 9/19/2014
Requests Stockouts Turnover
147
0
16.96
57
0
6.67
23
0
2.39
175
0
20.27
144
0
16.76
236
0
28.67
168
0
19.4
75
0
8.47
118
0
14.08
1,143
Fill Rate

0
100.00%

Appendix V ― Premarin 0.625 mg Results

Premarin 0.625 mg
Base
Altus
Barksdale
Langley
Little Rock
Minot
Moody
Wright Patterson
Total

Savings
Annual Expiration Average On-Hand
$722.76
$12,426.04
$2,607.48
$13,328.42
$8,184.86
$27,240.37
$480.56
$6,318.22
$494.72
$434.55
$480.56
$7,055.24
$3,305.75
$9,200.54
$16,276.67

$76,003.38
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1/1/2014 - 9/19/2014
Requests Stockouts Turnover
35
0
4.1
331
0
36.71
183
0
21.68
270
0
32.98
34
0
3.8
128
0
12.52
284
0
32.78
1,265
Fill Rate

0
100.00%

Appendix W ― Premarin 1.25 mg Results

Premarin 1.25 mg
Base
Barksdale
Columbus
Langley
Little Rock
Los Angeles
Luke
Robins
Seymour
Johnson
Travis
Tyndall
Total

Savings
Annual Expiration Average On-Hand
$3,591
$13,043
$2,158
$7,469
$5,127
$9,252
$1,452
$320
$2,919
$4,480
$2,197
$15,486
$726
$5,660

1/1/2014 - 9/19/2014
Requests Stockouts Turnover
140
0
16.58
39
0
4.88
16
0
9.61
99
0
40.75
7
0
4.39
64
0
7.8
41
0
5.18

$4,335
$4,403
$2,903

$10,525
$15,039
$6,593

24
36
32

0
0
0

$29,810

$87,867

498
Fill Rate

0
100.00%
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2.9
4.78
4.01

Appendix X ― Prograf 5 mg Results

Prograf 5 mg
Base
Lackland
Wright Patterson
Total

Savings
Annual Expiration Average On-Hand
$11,740.07
$13,796.89
$9,503.63
$44,340.32
$21,243.69

$58,137.21
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1/1/2014 - 9/19/2014
Requests Stockouts Turnover
8
0
4.7
6
0
2.61
14
Fill Rate

0
100.00%

Appendix Y ― Sandostatin 30 mg Results

Sandostatin 30 mg
Savings
Base
Annual Expiration Average On-Hand
Keesler
$3,913.85
$11,269.88
Lackland
$0.00
$12,452.74
Total

$3,913.85

$23,722.62
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1/1/2014 - 9/19/2014
Requests Stockouts Turnover
9
0
4.18
2
0
0.93
11
Fill Rate

0
100.00%

Appendix Z ― Spiriva 18 mcg Results

Spiriva 18 mcg
Base
Barksdale
Goodfellow
Los Angeles
Malmstrom
Maxwell
Mt Home
Patrick
Robins
Vandenberg
Wright
Patterson
Total

Savings
Annual Expiration Average On-Hand
$2,711.87
$22,259.02
$2,770.47
$3,362.84
$44.82
$2,085.01
$411.39
$1,191.36
$1,450.25
$16,035.68
$41.16
$3,252.01
$45.32
$6,623.57
$1,305.60
$4,505.91
$493.92
$1,690.42

1/1/2014 - 9/19/2014
Requests Stockouts Turnover
629
0
89.14
137
0
45.59
144
0
52.81
247
2
76.39
717
2
99.75
191
0
55.73
1185
0
12.81
460
2
77.83
156
4
50.28

$398.84

$12,970.78

1735

1

$9,673.62

$73,976.60

5601
Fill Rate

11
99.80%
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118.28

Appendix AA ― Tamiflu 75 mg Results

Tamiflu 75 mg
Base
Barksdale
Lackland
Langley
McConnell
Seymour
Johnson
Sheppard
Vance
Total

Savings
Annual Expiration Average On-Hand
$1,228.76
$2,554.66
$4,546.67
$16,294.80
$5,527.35
$9,218.76
$600.00
$1,087.71

1/1/2014 - 9/19/2014
Requests Stockouts Turnover
181
6
26.23
294
16
37.06
92
0
18.45
33
0
11.42

$216.41
$497.72
$415.49

$550.44
$1,401.89
$1,098.61

18
155
12

0
41
0

$13,032.38

$32,206.87

785
Fill Rate

63
91.97%

88

6.27
43.19
4.53

Appendix AB ― Tobradex 5 ml Results

Tobradex 5ml
Base
Wright Patterson
Total

Savings
Annual Expiration Average On-Hand
$8,678.88
$17,024.00
$8,678.88

$17,024.00
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1/1/2014 - 9/19/2014
Requests Stockouts Turnover
45
0
21.36
45
Fill Rate

0
100.00%

Appendix AC ― Votrient 30 mg Results

Votrient 30 mg
Savings
Base Annual Expiration Average On-Hand
Travis
$17,207.21
$10,357.55

1/1/2014 - 9/19/2014
Requests Stockouts Turnover
4
0
2.2

Total

4
Fill Rate

$17,207.21

$10,357.55
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0
100.00%

Appendix AD ― Vytorin 10 mg Results

Vytorin 10 mg
Savings
Base
Annual Expiration Average On-Hand
Andrews
$1,683.18
$12,108.50
Barksdale
$1,214.87
$6,199.59
Buckley
$1,306.10
$7,362.74
Columbus
$457.95
$1,337.17
Langley
$328.50
$11,055.92
Maxwell
$437.84
$1,039.24
Mt Home
$281.06
$458.98
Sheppard
$1,424.22
$6,463.78
Travis
$1,153.23
$14,196.20
Total

$8,286.93

$60,222.12
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1/1/2014 - 9/19/2014
Requests Stockouts Turnover
25
0
11.15
37
0
16.87
21
0
11.94
4
0
2.79
34
0
15.79
250
0
57.58
17
0
10.45
34
0
11.84
119
0
33.16
541
Fill Rate

0
100.00%

Appendix AE ― Zemplar 4 mg Results

Zemplar 4 mg
Savings
Base
Annual Expiration Average On-Hand
Lackland
$0.00
$10,159.68
Total

$0.00

$10,159.68
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1/1/2014 - 9/19/2014
Requests Stockouts Turnover
1
0
1.39
1
Fill Rate

0
100.00%

Appendix AF ― Zytiga 250 mg Results

Zytiga 250 mg
Savings
Base
Annual Expiration Average On-Hand
Andrews
$1,952.87
$15,548.23
Travis
$10,854.72
$39,530.84
Total

$12,807.59

$55,079.07
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1/1/2014 - 9/19/2014
Requests Stockouts Turnover
14
0
6.5
14
3
13.93
28
Fill Rate

3
89.29%

Appendix AG ― Quad Chart

94
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